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Lysosomal cysteine proteinase cathepsin B (CTB) is a member of the cysteine protease family 
known to participate in intracellular degradation processes and protein turnover in the lysosomes 
of healthy cells. Cathepsin B plays a crucial role in tumor invasion and progression by controlling 
extracellular degradation and participating in a proteolytic cascade activation (Gondi and Rao 
2013). Its role in tumor invasion and progression makes CTB a promising biomarker and target 
for antibody-directed prodrug therapy (Dheer, Nicolas et al. 2019). The development of novel 
CTB-specific molecular probes opens new possibilities for image-based diagnostic methods for 
different types of cancers (Podgorski and Sloane 2003, Tan, Peng et al. 2013). Since aberrant 
expression of this protein has been an indicator of cancer development, detecting CTB expression 
and activity might be beneficial for the early detection of cancer or revealing aggressive lesions 
(Gondi and Rao 2013). Developing probes capable of binding with CTB is challenging due to 
binding site homology to other members of the cysteine cathepsin family (Turk, Stoka et al. 2012). 
In this study, to identify unique residues in human CTB compare to other members of the cathepsin 
family, amino acid sequences of these proteins were exposed to. multiple sequence alignments. 
Cathepsin B in humans has three active site residues critical for catalysis: Cys108; His278, and 
Asp298 (Ruan, Hao et al. 2015) were confirmed with multiple sequence alignment as fully 
conserved residues. The initial step in the development of a detection assay for CTB is finding 
appropriate fluorescent small molecules for enzyme binding. In this study, two ligand candidates 
CID8795 and CID535684 were identified and successfully conjugated to the dye ATTO680 and 
were tested for binding affinity and specificity to CTB. For CID535684ATTO680, no binding 
interaction was observed in the fluorescence polarization (FP) assay. CID8795ATTO680 
demonstrated increases in fluorescence polarization assays in the presence of CTB with the half-
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maximal effective concentration (EC50) at 3.27 ± 1.27 nM. A third probe, Benzyloxycarbonyl 
(Cbz)-Lys-Lys-p-Aminobenzyl alcohol (PABA)-2’, 7’-dichloro-6’-methoxy-fluorescein (DCMF), 
was designed based on a known substrate scaffold for CTB. This novel substrate-based fluorescent 
probe was shown to be hydrolyzed by CTB having a specificity constant kcat/KM = 41.9 ± 0.07 
mM-1 × s-1. Finally, we investigated single nucleotide polymorphisms (SNPs) within the coding 
region of the CTSB gene within the general population (random data from 2,504 samples) included 
in the 1,000 Genomes project. The mapping of SNPs onto the 3D structure of cathepsin B indicates 
that the active site of CTB is fully conserved among humans – as no SNPs were identified within 
the binding pocket of CTB. According to these results, probes that bind to the enzyme’s active site 
should be generally useful for detecting CTB in all populations studied in the 1,000 Genomes 
project. 
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Chapter 1: Introduction 
1.1. Background 
According to the Canadian Cancer Society, approximately 50% of all Canadian people are 
expected to develop cancer (Ahmed and Shahid 2012, Turk, Stoka et al. 2012). Cathepsins are 
proteases that are commonly found in the lysosomes of healthy cells. Cysteine cathepsins belong 
to the family of papain-like cysteine proteases. These enzymes have unique active-site properties 
and are found expressed in various healthy tissues. Cathepsins have known roles in extracellular 
space (Puri and Roche 2008, Wartmann, Mayerle et al. 2010), cytosol (Reiser, Oh et al. 2004, 
Sever, Altintas et al. 2007), and the nucleus (Goulet, Baruch et al. 2004, Alcalay, Sharma et al. 
2008, Chen, Dong et al. 2017). Additionally, substantial evidence confirms the role of cathepsins 
in many physiologic and pathophysiologic cellular processes, including digestion and regulation 
of other proteases (Turk, Stoka et al. 2012). Classification of different cathepsins are based on the 
active site amino acids responsible for peptide hydrolysis: serine (cathepsins A and G); aspartic 
(cathepsins D and E), and lysosomal cysteine cathepsins consisting of eleven different proteases 
(cathepsins B, C, L, O, S, W, V, F, H, K, X, and Z), (Reiser, Adair et al. 2010). In general, 
cathepsins are capable of efficiently cleaving a variety of protein and peptide-based substrates 
while having high stability in acidic environments characteristic of the lysosome as well as 
endosomes. In addition to the normal function of this family, many studies performed using human 
tumor samples have implicated several cathepsins in cancer invasion and progression (Gocheva, 
Zeng et al. 2006). To date, cathepsins B, L, S, X are recognized to play pivotal roles in cancer 
progression. According to a recent report, cathepsin S is found in the serum of gastric cancer 
patients (Liu, Liu et al. 2016). Additionally, other reports confirmed the overexpression of 
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cathepsins L and X in gastrointestinal stromal tumors and gastritis and gastric cancer, respectively 
(Fox, Batchelder et al. 1995, Miyamoto, Iwadate et al. 2011).  
A review of the scientific literature demonstrates that cathepsin B plays a critical role in 
cancer as it is involved in a variety of pathological processes (Gondi and Rao 2013). In this study, 
our focus is on CTB, since it has great importance to cancer therapy (Gondi and Rao 2013). In 
humans, CTB is encoded by the CTSB gene, which is located on the short arm of chromosome 8. 
CTB has comprised of two chains: a heavy chain (amino acid 129-333 with a molecular weight of 
25-26 kilodaltons (kDa)) and a light chain (amino acid 80-126 with a molecular weight of 5 kDa) 
with a total molecular weight of 38 kDa; (Mach, Stuwe et al. 1992, Iacobuzio-Donahue, Shuja et 
al. 1997). CTB is expressed as an inactive zymogen that requires proteolytic processing to become 
catalytically active within the low pH environment of the lysosomes (Turk, Stoka et al. 2012, 
Aggarwal and Sloane 2014). This enzyme participates in intracellular degradation and protein 
turnover and possesses both endopeptidase and exopeptidase activity (Sosic, Mirkovic et al. 2013). 
Overexpression of CTB has been reported in human prostate, colorectal, glioma, melanoma, and 
breast cancers in humans (Gondi and Rao 2013). Experimental and clinical evidence has linked 
CTB to tumor invasion and metastasis (Podgorski and Sloane 2003, Li, Chen et al. 2011, Aggarwal 
and Sloane 2014). CTB has been proposed as a biomarker for various cancers (Terasawa, Hotani 
et al. 2015, Chen, Dong et al. 2017) and represents a potential target for diagnostic purposes and 
the monitoring of treatment outcomes. The enzyme is generally found in the lysosomes but is 
excreted into the extracellular matrix (ECM) during cancer progression (Szpaderska and 
Frankfater 2001). A variety of techniques have been developed for monitoring the expression of 
CTB, including DNA, RNA, or nucleic acid sensors (Nguyen, Lee et al. 2019). A variety of optical 
imaging methods have also been developed for studying CTB activity in cell and animal studies. 
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These methods rely on the design and synthesis of fluorogenic probes capable of detecting protease 
activity in complex biological mixtures (Lai, Chang et al. 2004, Dai and Kool 2011).  
1.2. Research Problem and Hypothesis  
Due to the roles of CTB in cancer progression and invasion (Duffy 1992), this enzyme has 
been targeted for the design of specific inhibitors to prevent activity and, as a result, inhibit tumors 
from metastasizing. This approach faces two main challenges: first: other members of this family, 
especially cathepsin K (CTK) and cathepsin L (CTL) can compensate for the loss of CTB activity; 
second: the active site residues in CTB are common to most members of this family (Khouri, 
Plouffe et al. 1991). Although these are considerable challenges for inhibitor design, they are less 
challenging for the design of diagnostic probes, since the diagnostic probes can target the amino 
acids within close distance of the active site residue for binding interaction. Evaluation of CTB 
activities associated with tumors by fluorescent probe considered to be a diagnostic or therapeutic 
target for different types of cancer.  (Alford, Ogawa et al. 2009, Ofori, Withana et al. 2015, Kramer, 
Renko et al. 2017). Molecular imaging probes do not need to bind directly to the active site of the 
enzyme, but they still could bind to distant pockets within the protein allowing for more flexibility 
in the design of probes specific to CTB. This flexibility is absent in the design of inhibitors and 
probes that depend on enzymatic activity for activation. Besides, similar to CTB, overexpression 
of CTK and CTL has also been associated with tumor progression and invasion (Podgorski, 
Linebaugh et al. 2009, Sui, Shi et al. 2016), and may serve as a biomarker for cancers; therefore, 
small organic molecules intended for use as molecular probes may not need the same degree of 
specificity as inhibitors of CTB activity. Since the role of CTB in cancer progression has been 
proven clinically (Podgorski and Sloane 2003, Gondi and Rao 2013, Aggarwal and Sloane 2014), 
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targeting the over-activity or overexpression of this protein with fluorescent small molecules may 
be used as a promising approach for cancer detection (Li, Chen et al. 2011, Gondi and Rao 2013).  
Currently, two classes of fluorescent molecular probes targeting proteases have been 
reported in the literature (Blum, Weimer et al. 2009): 1) activity-based probes (ABPs) that are 
covalent inhibitors and can be made in a quenched form (Kato, Boatright et al. 2005, Ofori, 
Withana et al. 2015), and an unquenched from (Blum, von Degenfeld et al. 2007), 2) probes that 
act as a substrate and become detectable or fluorescent upon enzymatic cleavage (Chowdhury, 
Moya et al. 2014, Garland, Yim et al. 2016, Wang, Li et al. 2016, Chen, Lee et al. 2017).  
In addition to these probes, there is another series of probes (with no inhibitory activity)that 
are unquenched and do not need enzymatic activation for becoming fluorescent (Du, Moulick et 
al. 2007).  
The two best examples of quenched ABPs before enzyme activation would be MB-074 
(Ofori, Withana et al. 2015) and 6QCNIR (Ofori, Withana et al. 2015) reported by Dr. Matthew 
Bogyo. Matthew Bogyo designed and synthesized a series of elegant activity-based, near-infrared 
(NIR) fluorogenic probes (Kato, Boatright et al. 2005, Blum, von Degenfeld et al. 2007) for CTB 
that were used in cell and animal studies as well as to identify tumor margins during surgery (Kato, 
Boatright et al. 2005, Verdoes, Bender et al. 2013, Ofori, Withana et al. 2015). An example of 
unquenched ABPs would be Carbo benzoxy-capped Phe-Lys(Cy5)-acyloxymethyl ketone (GB123) 
designed by Blum group (Blum, von Degenfeld et al. 2007) which freely penetrates cells and has 
a bright signal accumulation in the living mice tumor. The ABPs (quenched and unquenched) 
irreversibly bind to the active site of the specific enzyme classes; therefore, despite their favorable 
outcome these probes still suffer from the number of limitations: 1) lack of selectivity when most 
of the family of the target enzyme share the common active site residues; 2) 1:1 stoichiometry 
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between probe and protein and lack of amplification by multiple processing events; 3) trapping in 
the lysosome. 
An example of a substrate-based probe is Cbz-Lys-Lys-PABA-7-Amino-4-methylcoumarin 
(AMC) (Chowdhury, Moya et al. 2014), which was reported to be highly selective toward human 
CTB in live cells over other members of the cathepsin family (Chowdhury, Moya et al. 2014). 
Other similar probes include Cbz-Arg-Arg-AMC (Khouri, Plouffe et al. 1991), which is shown in 
Figure 1. A significant problem facing these probes is that they compete with the high fluorescent 
background of live cells due to autofluorescence (λem = 420–470 nm) (Andersson, Baechi et al. 
1998) and the released fluorophore AMC rapidly diffuses out of cancer cells. 
 
Figure 1. The chemical structure of Cbz-Arg-Arg-AMC. 
 
The fluorescently labeled Geldanamycin (GM-cy3B) would be an example of an 
unquenched probe that does not require protein activation to become fluorescent, reported by the 
Moulick group (Du, Moulick et al. 2007). They identified the high affinity and specificity of GM-
cy3B toward heat shock protein 90 (Hsp90) with EC50 value at 58.5 ± 20 nM with fluorescence 
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polarization assay in breast cancer cell line. There was no example of this type of probes toward 
CTB reported in the literature.  
1.3. Research Strategy  
To circumvent the obstacles mentioned above, as an alternative to ABPs, using substrate-
based probes as reporters can be beneficial for signal amplification due to the processing of many 
substrates by an enzyme over time. The substrate-based probes require CTB catalytic activity for 
activation and the release of a fluorophore or quencher.  
Using a fluorophore with a certain wavelength, preferably above autofluorescence of the live 
cells and ideally in the near-infrared (spectral range from 650 to 900 nm) part of the 
electromagnetic spectrum (Kisin-Finfer, Ferber et al. 2014), would be beneficial to distinguish 
between the signal releasing from the substrate hydrolysis and background. Near-infrared probes 
have an advantage over other conventional probes (spectral range from 380 to 650 nm) in cellular 
and tissue imaging because of the low absorption of the excitation radiation by endogenous 
biological molecules at higher frequencies. Moreover, at the NIR range, there is less 
autofluorescence compared to visible wavelengths – allowing for a higher signal-to-noise level 
(Zhang, Bloch et al. 2012). Besides that, using NIR probes enable scientists to achieve imaging in 
deeper tissues due to their longer excitation wavelengths (Chen, Lee et al. 2017). Recently, these 
probes have become favored due to their low interference and reduced damage to living cells. Past 
research has been dedicated to designing NIR probes and substrates for CTB (Habibollahi, 
Figueiredo et al. 2012, Kisin-Finfer, Ferber et al. 2014, Wang, Li et al. 2016, Chen, Lee et al. 
2017). An example of the substrate-based probe with NIR spectrum is the cathepsin B glycol 
chitosan nanoparticle (CB-CNP) with chemical structures of Cy5.5, BHQ-3, containing NIR dye 
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(Cy5.5) with the λex = 678 nm and λem = 694 nm and a quencher (BHQ-3) which was reported by 
Ryu group (Ryu, Na et al. 2014) (Figure 2).  
 
 
Figure 2. The chemical structure of CB-CNP, Cy5.5 (dye), and BHQ-3 (quencher). 
Adapted from:(Ryu, Na et al. 2014) 
 
The next strategy requires selecting the fluorophore to cover a broad range of pH – ideally 
acidic pH (pH of the lysosome (5.5) in which CTB is localized) (Bohley and Seglen 1992). 
Cyanine dye would be a great example of covering the wide range of pH (6.0–8.0), although it 
subsequently loses its fluorescent characteristics in the less acidic environment (Briggs, Burns et 
al. 2000).  
In addition to the substrate-based probe, designing the unquenched, non-reactive probes 
which efficiently and tightly bind to the protein with no inhibitory activity – thereby revealing 
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enzyme accumulation in tissues, would be another strategy. This strategy brings novelty to our 
study, as there are no examples of these types of probes for measuring CTB overexpression.  
For resolving the limitations mentioned above and obtaining a direct measurement of CTB 
overexpression in the context of tumor metastasis and progression, two non-reactive NIR 
fluorescent probes and one substrate-based probe were synthesized and evaluated in this study.  
For non-reactive probes, the initial step was selecting computationally identified ligands 
from previous work reported by Kamstra et al. (Kamstra and Floriano 2014) and converting them 
into fluorescent probes through conjugation to a dye having NIR emission in the range of 700 nm. 
All the ligands identified by the Kamstra group contain an amine group which can react with an 
amine-reactive fluorophore for conjugation. ATTO-TEC offers a variety of new generation 
fluorescent dyes for amino groups labeling with the spectral region from 350 nm to 750 nm 
(Buschmann, Weston et al. 2003). The most common amine-reactive group in commercial dyes 
among these derivatives is the dye contains N-hydroxysuccinimide (NHS)-esters group (Hughes, 
Rawle et al. 2014). ATTO680 NHS-esters with excitation and emission in the NIR spectral range 
(λex = 675 nm and λem = 707 nm) were selected for forming a chemically stable amide bond with 
the subjected ligands. ATTO680 NHS-esters is a hydrophilic fluorophore with a fluorescence 
lifetime of 3.04 nanosecond (ns) (Buschmann, Weston et al. 2003, Hughes, Rawle et al. 2014). 
The hydrophilic characteristic of this dye allows better utilization in vitro and in vivo. One of the 
most important characteristics of the dye which has a strong effect on fluorescence polarization is 
a lifetime. Fluorophores with lifetimes above 3 ns, are considered  suitable for providing a distinct 
FP between free fluorophore and fluorophore bound with protein (molecular weight above 10 kDa) 
(French, Burton et al. 2000, Owicki 2000). To increase specificity towards CTB, the probes were 
selected based on predicted contacts to unique residues in the active site of CTB. These probes 
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were synthesized and subjected to inhibition and fluorescence polarization assays to confirm 
binding to CTB. 
Besides, we reassessed the scaffold used to produce substrates previously developed with 
Dr. Phenix’s group (Chowdhury, Moya et al. 2014). Here, a similar substrate-based probe was 
designed and synthesized but with the dye, DCMF (Figure 26) as a fluorophore, instead of AMC. 
This new probe would be expected to be quenched in the intact substrate but have fluorescence 
emission at higher wavelengths upon CTB cleavage (DCMF λem = 522 nm). Having an improved 
fluorescent reporter should lead to lower background noise while also maintaining fluorescence at 
low pH (Mugherli, Burchak et al. 2006). In an activity assay toward two proteases proteins (CTL 
and CTB), we confirmed the binding affinity and selectivity of this probe toward CTB. 
Finally, the International Genome Sample Resource (IGSR) (1,000 Genomes database) 
(IGSR: The International Genome Sample Resource 2015, June 30) was used to investigate single 
nucleotide polymorphisms present in the gene encoding CTB in human populations. This was done 
for two main reasons: first, to detect any mutations located on the CTSB gene, that may be involved 
in the development of cancers; second, to determine if there are SNPs in the population (1,000 
Genomes project) that prevent binding of the developed probes to the protein, CTB.  
1.4. Research Significance  
In this study, the two novel NIR fluorescent non-reactive probes: CID8795ATTO680 
(Figure 27) and CID535684ATTO680 (Figure 28) and a novel substrate-based fluorescent probe 
Cbz-Lys-Lys-PABA-DCMF (Figure 31) for CTB were synthesized, characterized, and evaluated 
in preliminary biochemical studies. This study attempts to overcome the limitations mentioned 
above, including overcoming the low specificity of existing probes towards CTB due to high active 
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site homology with other members of the cysteine protease family. Also, the expansion of the 
number of CTB probes that have excitation and emission wavelengths beyond autofluorescence 
associated with live cells. To accomplish this, we describe the synthesis of a non-reactive probe 
(CID8795ATTO680 Figure 27) and its evaluation as a NIR probe for detecting CTB. 
Additionally, we describe the development of a new CTB substrate (Cbz-Lys-Lys-PABA-DCMF 
Figure 31). These probes would be an excellent low-cost method for CTB detection in cancer as 





Chapter 2: Literature Review  
Currently, cancer is the most common cause of death in Canada leading to intense research 
into finding better diagnostic techniques and potential cures (Public Health Agency of Canada 
2010, March 29). So far, more than 7000 reviews have confirmed the presence of proteases playing 
an important role in various types of cancers (Emmert-Buck, Roth et al. 1994), (Bohley and Seglen 
1992), (Aggarwal and Sloane 2014). Cathepsins are a diverse group of proteases categorized into 
different families based on their active site structure – each of which employs a different catalytic 
nucleophile (e.g. aspartate, serine or cysteine) that efficiently hydrolyzes peptide bonds in the 
acidic environment of the lysosome (Bohley and Seglen 1992, Jedeszko and Sloane 2004, Patel, 
Homaei et al. 2018). The cysteine cathepsin family is responsible for protein turnover in many 
normal physiological processes but are linked to a variety of disease processes, including: 
Alzheimer's disease; pancreatitis; osteoarthritis; several ocular disorders, and different types of 
cancers (Lai, Chang et al. 2004, Im, Venkatakrishnan et al. 2005, Hook, Jacobsen et al. 2015, 
Oortveld, van Vlijmen-Willems et al. 2017, Vizovisek, Fonovic et al. 2019).  
Among all members of the cysteine cathepsin family, cathepsin B has high expression in 
normal tissues, such as thymus; blood; corpus callosum; pituitary gland, and low expression in 
heart and uterus (UCSC Genome Browser 2013, Dec). The role of CTB in cancer-promoting 
processes includes several steps: the first step of the cancer progression requires the surrounding 
tissue to be cleared and the degradation of the extracellular matrix creating a pathway for tumor 
growth. This is followed by its involvement in the proteolytic cascade – a complex and redundant 
network of protease enzymes that are responsible for regulating another protease activity. For 
example, cysteine cathepsins help to activate matrix metalloproteinase and urokinase plasminogen 
activator resulting in further tissue invasion. The last step is E-cadherin cleavage at cadherin 
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junctions, which allows cancer cell migration (Kobayashi, Moniwa et al. 1993, Guo, Mathieu et 
al. 2002). These steps are summarized in Figure 3 and Figure 4. 
 
 
Figure 3. Involvement of cysteine cathepsins in cancer progression. Cancer can progress in two steps: 








Figure 4. The three different mechanisms of the cathepsin B involvement in the activation of the 
proteolytic cascade. Cathepsin B could involve in this process in different ways: degradation of the 
extracellular matrix; converting pro-MMP to MMP, and activation of the pre-TGF-B1 to TGF-B1. 
Adapted from: Lampe CM, Gondi CS (2014) cathepsin B Inhibitors for Targeted Cancer Therapy. 
 
Initially, cancer cells undergo sequential steps, which include tissue architecture disruption 
by modulation of cell-matrix and cell-cell contacts. The epithelial-to-mesenchymal transition 
(EMT) controls the flexibility of cancer cells. This mechanism is also involved in wound healing 
and organism development under normal physiological conditions. During EMT, cells lose their 
polarity and connections and obtain pro-migratory characteristics to cross the extracellular matrix 
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(ECM) or the basement membrane. Indeed, EMT contributes to increased cancer cell motility, 
invasion, and progression (Thiery, Acloque et al. 2009, Micalizzi, Farabaugh et al. 2010, Kryczka, 
Papiewska-Pajak et al. 2019). Recent studies suggest a role of protease activity in areas of the cell 
which have direct contact with the ECM; therefore, precisely controlling cell invasion in vivo 
(Rottiers, Saltel et al. 2009). The role of cathepsins in both tumor progression and metastasis 
supported by numerous clinical reports – although the precise mechanisms are still not clear 
(Gocheva, Zeng et al. 2006, Bakst, Xiong et al. 2017). As an oncogenic role of cathepsin B, this 
protein interacts with cystatins (Pavlova and Bjork 2003) and annexin II tetramer (p11) (Ma, Finley 
et al. 2000). These interactions put CTB at key positions for the proteolytic activation of ECM; 
therefore, inducing ECM degradation. The active role of cathepsin B in initiating the proteolytic 
cascade has been confirmed with various studies, which include involving: urokinase-type 
plasminogen activator (uPA); plasminogen to plasmin, and activation of latent transforming 
growth factor-beta (TGF-β) (Somanna, Mundodi et al. 2002). Cathepsin B appears to increase the 
activity of the matrix metalloproteinase (MMPs) by destroying their inhibitors, thereby enabling 
ECM degradation (Kostoulas, Lang et al. 1999). The CTSB gene activation in cancer cells is 
mediated by extracellular signals. These signals indeed are mediated through the urokinase 
plasminogen activator receptor (uPAR)-uPA-integrin and the cell surface adhesion receptor 
(CD44)-MMP, resulting in overexpression of CTB mRNA and processed to pro-cathepsin B. The 
pro-cathepsin B activation goes through multiple mechanisms such as tissue plasminogen activator 
(tPA) and uPA). Of note, the essential role of CTB for organizing protease cascade and addressing 




Figure 5. Representation of signaling and protease cascade events induced by cathepsin B on cancer 
cells. 
 
Furthermore, the function of CTB for activation of trypsinogen-1 in pancreatitis was 
confirmed by Lindkvis’ group (Lindkvist, Fajardo et al. 2006); pancreatic inflammation induces 
the risk of pancreatic cancer (Whitcomb 2004). In 2012, Garcia-Cattaneo reported the signaling 
and cleavage of toll-like receptor 3 (TLR3) dependency on cathepsin B (Garcia-Cattaneo, Gobert 
et al. 2012). The TLR3 activation is also known to enable apoptosis in tumor cells through caspases 
8 and 9 activations (Sun, Zhang et al. 2011). Cathepsin B directs tumor cells to survive by 
inactivation of the TLR3-mediated apoptotic pathway.  
Cathepsin B activity has a dual nature that could serve as a pro-oncogenic molecule (involve 
in ECM degrading, angiogenesis, and metastatic inducing) and anti-apoptotic molecule (involve 
in autophagy and immune response). The low pH dependency of CTB activity is significant due 
to the observation of the same environment around the invasive front of the tumor cells (more 
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acidic than normal cells), (Tannock and Rotin 1989). This confirms the hypothesis that the tumor 
microenvironment (low pH) promotes CTB activity. Cathepsin B is localized in the lysosomes 
(Bohley and Seglen 1992); it was also reported to be localized in the mitochondria (Frohlich, 
Schaumburg-Lever et al. 1993) where cell death is initiated (Muntener, Zwicky et al. 2004).  
Studies have shown that CTB hydrolytic activity can be targeted to release drugs for anti-
cancer therapy (Wei, Gunzner-Toste et al. 2018). Cathepsin B has also been reported to be a 
potential diagnostic target for different types of cancers (Campo, Munoz et al. 1994, Ruan, Hao et 
al. 2015). Researchers have attempted to design specific inhibitors of CTB activity to impede 
tumor metastasis. For example, the Fox group in 1992 reported a synthetic inhibitor (PCB1) for 
cathepsin B with yielding the Ki at 0.4 nM (Fox, Demiguel et al. 1992). Also, in 2013, Izidor Sosic 
and his team described a reversible inhibitor (nitroxoline (5-nitro-8-hydroxyquinoline)) to inhibit 
endopeptidases activity of the CTB (Sosic, Mirkovic et al. 2013). However, this approach has 
many limitations, primarily due to the overlapping activity and redundancy of cysteine cathepsin 
activity in tumor progression (Aggarwal and Sloane 2014). For example, any therapeutic benefits 
of CTB inhibition are blunted by the compensation of proteolytic activity of cathepsin K and L 
leading to tumor metastasis. This overlapping proteolytic activity results from high homology of 
the residue of the active site between most of the members of this family with CTB thus making 
selective probes and inhibitors a major challenge (Gopinathan, Denicola et al. 2012, Loser and 
Pietzsch 2015). Designing a probe selective for human CTB localization and detection in vitro and 
in vivo would be useful for investigating the role of this protease in cancer (Wang, Li et al. 2016). 
There have been numerous reports that describe the design and synthesis of activity-based and 
substrate-based molecular imaging probes studying CTB activity in cells and animals (Blum, von 
Degenfeld et al. 2007, Kisin-Finfer, Ferber et al. 2014, Lee, Kim et al. 2014, Mertens, Schmitz et 
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al. 2014, Tian, Li et al. 2014, Wang, Li et al. 2016), and as well, tools for surgical resection to 
identify tumor margins (Ofori, Withana et al. 2015). 
The first series of probes for CTB localization and detection would be activity-based probes, 
which are suicide inhibitors, allow dynamic monitoring of protease activity. These activity-
dependent small molecules are processed by the enzyme into a reactive intermediate and 
covalently bonds a reporter group to the target protease; therefore, it provides the activity level of 
proteases in cell or tissue (Verdoes, Oresic Bender et al. 2013). The activity-based probes 
covalently bind to the target enzymes while simultaneously releasing a quenching group, thereby 
generating enhanced fluorescence and allowing localization of the target. The first example of 
ABPs was reported by Bogyo in 2005, the Bogyo group, via exploring irreversible inhibitors, 
developed activity-based fluorescent probes for CTB; however, these probes also reacted 
efficiently with CTL (Blum, Mullins et al. 2005, Blum, von Degenfeld et al. 2005). Bogyo and his 
team in 2007, also reported the fluorogenic mechanism-based inhibitors using acyloxymethyl 
ketone (AOMK) as a reactive group. The reaction mechanism of the AOMK group with Cysteine 
active site illustrates in Scheme 1. This series of probes were quenched before being recognized 






Scheme 1: Covalent labeling of cathepsin active sites by employing AOMK inhibitors. (A) The 
reaction mechanism of the AOMK inhibitors; (B) Quenched activity-based probes (Blum, von Degenfeld 
et al. 2007). The fluorescence of probes is low. Prior to enzymatic labeling since the fluorophore (Cy5), 




Although these probes are excellent for profiling CTB and CTL in human models of cancer 
with high enzyme expression, this strategy suffers from a 1:1 stoichiometry between probe and 
enzyme. In cases where CTB expression is low, the fluorescent signal may be below detection 
limits and some derivatives suffer from a small fluorescence turn-on ratio.  
Alternately, substrate-based probes for CTB may have enhanced sensitivity in vitro and in 
vivo compared to the activity-based probes since one enzyme can continuously activate multiple 
substrates leading to the accumulation of the fluorescent reporter group (Ryu, Na et al. 2014). 
Substrate-based probes for detecting protease activity are attractive since they can be quenched in 
the intact peptide; therefore, they have low background signals until hydrolysis and activation by 
the target enzyme.  
The simplest examples of a fluorogenic substrate-based probe is a short peptide sequence 
attached to a quenched dye, such as Ac-Arg-Arg-7-Amino-6,8-difluorocoumarin (AFC) 
(commercial substrate for CTB) or Z-Phe-Arg-AMC (commercial substrate for CTB and CTL) 
(Los, Walczak et al. 2000). The two dyes, 7-Amino-4-methylcoumarin (AMC) or 7-Amino-6,8-
difluorocoumarin (AFC) have been conjugated to a tetra-peptide cleavage site generating probes 
for caspase (Thornberry, Chapman et al. 2000). The general design and mode of action of these 




Figure 6. The mode of action of the fluorescent FRET-based probe. 
During 2014, Ryu and his researchers reported a highly sensitive substrate-based probe for 
CTB consisting of a self-quenching CTB-cleavable peptide and chitosan nanoparticles (Ryu, Na 
et al. 2014). Fujii and his team developed a substrate-based fluorescent small-molecule probe that 
becomes highly fluorescent upon CTB activation (Fujii, Kamiya et al. 2014). These probes showed 
low selectivity toward CTB suffering from cross-reactivity with CTL. Recently, Dr. Phenix group 
developed the Cbz-Lys-Lys-PABA-AMC fluorogenic probe with high specificity to CTB. 
Although this probe is rapidly and selectively hydrolyzed by CTB, AMC readily diffuses out of 
the lysosomes thus rapidly losing fluorescent signals and requires excitation wavelengths that 
induce intracellular autofluorescence (Chowdhury, Moya et al. 2014). Others built upon this 
strategy by designing a substrate that employed the Cbz-Lys-Lys-PABA scaffold but used a 





In addition to ABPs and substrate-based probes, there is another group of the small 
fluorescent molecule which are unquenched and do not need proteins for activation (non-reactive 
probes). Non-reactive probes refer to small-molecule fluorescent probes (unquenched) that bind 
to a protein and can potentially be measured by fluorescence polarization assays in vitro. 
Performing fluorescence polarization in vivo is challenging due to the lack of cellular spatial 
resolution, in addition to the potential to make temporal measurements (Piston 2010, Vinegoni, 
Dubach et al. 2016). Despite that, Dubach and co-workers in 2014, reported a ) live-cell imaging 
technique to locate and profile fluorescent small molecules, and target interaction in real-time at 
subcellular resolution in vitro and in vivo (Dubach, Vinegoni et al. 2014). Fluorescence 
polarization assays have been applied to study protein-protein, protein-DNA, and protein-ligand 
molecular interactions analysis (Jameson and Ross 2010). In 2007, Yuhong Du group reported the 
non-reactive probe (GM-cy3B) for Hsp90 which is an important target for cancer. They 
successfully measured the binding interaction of this protein toward their probe by fluorescence 
polarization in vitro (Du, Moulick et al. 2007). However, there is no example of non-reactive 
probes for CTB.  
Overall, the limitations that we need to address in this study are as follow: 1) low selectivity 
of the probe toward CTB, due to active site homology of this protein with other members of 
cathepsin family, 2) the inhibitory effects of the probe toward CTB, due to compensatory feature 
of other members of this family for the loss of CTB activity, 3) high fluorescent background of 
live cells due to intracellular autofluorescence (λem = 420–470 nm), 4) diffusion of the reporter 




To address these shortcomings, we synthesized and evaluated two novel probes for assessing 
overexpression of CTB; a non-reactive probe with the desired feature of non-inhibitory activity 
toward CTB (CID8795ATTO680 Figure 27) with emission and excitation wavelengths in the NIR 
range, and a substrate-based probe (Cbz-Lys-Lys-PABA-DCMF Figure 31) with high specificity 
and selectivity toward CTB with the fluorophore reporter (DCMF) with excitation (480 nm) and 






Chapter 3: Cathepsin B: Sequence, Structure, and Function 
3.1. Introduction 
In this chapter, we compared the nucleotide sequence of human CTB with other members 
of the cathepsin family to identify the unique residues in this protein and map them on the 3D 
structure of human CTB. Besides, the predict binding interaction of two subjected probes 
(CID8795ATTO680 and Cbz-Lys-Lys-PABA-DCMF) with human CTB is discussed. A variety 
of bioinformatics applications such as molecular docking and rational probe and drug design 
require a good understanding of functional sites within the target protein. The first strategy we 
employ is to compare the amino acid sequence of human CTB to other members of the cathepsin 
family to discover evolutionarily conserved residues that have functional activity. To predict the 
selectivity of novel probes, the active site residues of human CTB were compared to other 
members of the cathepsin family (in the same organism). Additionally, the 3D structure and 
binding pocket of CTB have been studied to assess the specificity of the probes. Finally, the two 
probes, CID8795ATTO680 and Cbz-Lys-Lys-PABA-DCMF, (docked structure with CTB) also 
screened to identify the binding interaction toward CTB (Daniel Tesolin, Private Communication) 
3.2. Procedure and Materials  
3.2.1. CTSB Gene 
Information about the CTSB gene (Homo sapiens) (ID: 1508) was found by searching 
through the NCBI gene bank (NCBI 2019, Aug).  
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3.2.2. CTB Protein 
General information about proteins such as the length of the amino acid sequence, number 
of chains, and name and position of the active site residues can be obtained from the UniProt 
website (UniProtKB 2018, Sep 09). The amino acid sequence of human CTB was retrieved from 
the UniProt website (UniProtKB 2018, Sep 09) and saved as FASTA format (Figure 8). This 
sequence was used for multiple sequence alignment with CLUSTALX-2.1 software (Clustal: 
Multiple Sequence Alignment AUG,2012).  
 
3.2.3. Similarity and Differences between Cathepsin B and Different Members of Cathepsin 
Family  
The amino acid sequences of human CTB and eleven members of the human cathepsin 
family were obtained from the UniProt website (UniProtKB 2018, Sep 09). We compared the 
amino acids sequence of human CTB to other members of the human cathepsin family to identify 
any dissimilarities in the active sites that could guide the design of probes with high specificity 
toward CTB (UniProtKB - P07858 (CATB_HUMAN) 2018, May 25, UCSC Genes 2018, NOV 
24, NCBI 2018, OCT 08) relative to other members of the cathepsin family. The CLUSTALX-2.1 
software was used to align the amino acid sequence of human CTB (UniProtKB - P07858 
(CATB_HUMAN)), the amino acid sequence corresponding to the human CTB crystal structure 
1HUC (amino acid sequence of mature enzyme), and eleven members of human cathepsin family 
including; cathepsins Z, L2, H, E, G, C, S, K, L1, L3, and, D. The reason for using CLUSTALX2.1 
software was to include the 1HUC amino acid sequence to limit the variable residues to those are 
within mature CTB.  
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The parameters used for running CLUSTALX-2.1 were as follows: substitution matrix: 
BLOSUM 30, gap opening penalty: 10, and gap extension penalty: 0.10. In the output of this 
program, the positions shown with "*" indicate the fully conserved residue and "-" indicate a gap, 
":" shows strongly conserved residue and. "." means the residue is weakly conserved. In general, 
conserved residues refer to a nucleotide or amino acid which is identical across or within the 
species. Fully conserved residue refers to a single residue that is conserved in all sequences 
compared. Strongly conserved residue indicates conservation between groups of amino acids 
which has strongly similar properties, in contrast, the weakly conserved residue indicates 
conservation between groups of amino acids which has poorly similar properties (Chenna, 
Sugawara et al. 2003). 
3.2.4. 3D Structure of CTB 
Experimentally determined 3D structure of human CTB were identified at the RCSB website 
(RCSB PDB 2018, OCT 30)The list of the PDB files for CTB are as follows: 2IPP; 1PBH; 2PBH; 
3PBH; 3AI8; 1HUC; 3CBJ; 3CBK; 3K9M; 1GMY, and 1CSB (RCSB PDB 2018, OCT 30). The 
1HUC structure is a complete and non-complex structure of human CTB which was used for 
molecular docking of CID8795ATTO680 and Cbz-Lys-Lys-PABA-DCMF by a collaborator 
Daniel Tesolin. The 1CSB is an inhibited complex structure of CTB in which the presence of ligand 
N-[(3R)-4-ethoxy-3-hydroxy-4-oxobutanoyl]-L-isoleucyl-L-proline (EP0) makes this structure a 
good target for analyzing the inhibitory interaction within the binding pocket of the protein. The 
3D structure of human CTB (1CSB) (RCSB PDB 2018, OCT 30) was used for visualization of the 
active sites and variable residues within the binding site with VMD software (VMD APR,2008). 
In addition to the 3D structure of CTB, the 3D structures of human cathepsin D and C were used 
to compare the results obtained from multiple sequence alignment. The PDB codes 1LYB and 
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3PDF which were obtained under the RCSB website (RCSB PDB 2018, OCT 30) used for 
visualizing the two adjacent histidines in human cathepsin D and C, respectively.  
3.2.5. Binding Interaction Analysis  
In this study, two probes (CID8795ATTO680 and Cbz-Lys-Lys-PABA-DCMF) were 
evaluated for binding interactions with CTB. For CID8795ATTO680-CTB visualization of the 
docked structure was done with the Molecular Operating Environment (MOE) software 
(Molecular Operating Environment MOE March,2020). This structure was kindly provided by 
Daniel Tesolin (Private Communication). To predict the binding interaction of Cbz-Lys-Lys-
PABA-DCMF-CTB, the docked structure of Cbz-Arg-Arg-AMC-CTB (Daniel Tesolin, Private 
Communication) was used as a surrogate. The standard view orientation of the binding site and 
target residues for the description of the protease-substrate interaction is shown in Figure 7 (Loser 
and Pietzsch 2015).  
 
Figure 7. Annotation of the protease-substrate interaction, where P positions refer to the positions of the 




3.3.1. CTSB Gene 
The CTSB (Homo sapiens) gene is a protein-coding sequence containing 15 exons with 9 of 
them are coding exons. The length of the CTSB gene is 25613 base pairs. The CTSB gene is located 
on the 8p22 chromosome in humans (Oliveira, Ferro et al.). The length of the transcript is 1017 
bps which are translated to 339 amino acids (Atlas of Genetics and Cytogenetics in Oncology and 
Haematology 2008, Aug). The protein encoded by the CTSB gene belongs to the superfamily of 
papain-like cysteine proteases.  
3.3.2. CTB Protein 
The protein encoded by the CTSB gene (Homo sapiens) contains one signaling peptide 
sequence located at positions 1-17 and one propeptide in the position of 18-79, both of which are 
cleaved during enzyme maturation and activation. CTB is comprised of a light chain containing 
47 amino acids from sequence 80 to 126 and a heavy chain located at positions 129-333 
(UniProtKB - P07858 (CATB_HUMAN) 2018, May 25). CTB is synthesized in the rough 
endoplasmic reticulum (RER) as a pre-proenzyme (the inactive form of the enzyme which needs 
modification for activation) with 339 amino acids. It also contains 17 amino acids, known as a 
signal peptide, that directs the protein to the lumen of RER. Pro-cathepsin B is formed by removal 
of the signaling peptide and is transferred into the Golgi apparatus through the RER where it is 
glycosylated at two asparagine residues. The N-linked glycans are mannose-containing 
oligosaccharides with phosphorylated mannose residues that bind to the mannose-6-phosphate 
receptors in the trans-Golgi leading to the transportation of the enzyme to the lysosomes via 
transport vesicles. In the acidic environment of the lysosomes, pro-CTB undergoes autocatalytic 
activation leading to the formation of the active and mature CTB. The final proteolytic event 
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occurs through cleavage between residues 47 and 50 to yield two chains (Turk, Kos et al. 2004, 
Aggarwal and Sloane 2014). Finally, in the acidic environment of the lysosome, the active CTB is 
formed (Rowan, Mason et al. 1992). This enzyme has both endopeptidase and exopeptidase 
activity (Hasnain, Hirama et al. 1993). In terms of endopeptidase activity, CTB can cleave peptide 
bonds in the interior of a protein sequence. The substrate-binding site of the enzyme is located 
between the two lobes where cysteine (Cys108) on the left section of the lobe acts as a catalytic 
nucleophile and is responsible for peptide bond cleavage. Cys108 is activated by His278 – which 
is located on the right lobe (by convention). 
Other active residues of the enzyme are Asn289 (Ruan, Hao et al. 2015), which provide the 
site where the substrates bind to the enzyme and the hydrolysis reaction takes place. Additionally, 
CTB can function as peptidyl dipeptidase which is responsible for dipeptides cleavage from the 
C-termini of the proteins. A unique feature of CTB is an occluding loop that allows this enzyme 
to hydrolyze dipeptides at the C-terminus acting as exopeptidase (Cygler, Sivaraman et al. 1996, 
Mort and Buttle 1997). The amino acid sequence in FASTA format of the CTB protein is shown 




Figure 8. Human cathepsin B amino acid sequence in FASTA format with the positions of three active 
site residues, Cys108, His278, and, Asn289, underlined in green. (NCBI 2018, Nov 13) 
 
3.3.3. Similarity and Differences between Cathepsin B and Other Members of the Cathepsin 
Family  
All general information about the human CTB and other members of the human cathepsin 
family was obtained from the UniProt website (UniProtKB 2018, Sep 09) (Table 1). This 
information reveals the active site homology of CTB with half of the cathepsin family. All the 




Table 1. Selected information of 12 human proteins from the Cathepsin family obtained from the UniProt 


















Cysteine protease which is participates in 
intracellular degradation and turnover of 
proteins. Has also been implicated in 
tumor invasion and metastasis 







Cysteine protease. May have an 
important role in corneal physiology 








Important for the overall degradation of 
proteins in lysosomes. 






May have a role in immune function. 
Probably involved in the processing of 
antigenic peptides during MHC class II-
mediated antigen presentation. May play 
a role in activation-induced lymphocyte 
depletion in the thymus, and neuronal 
degeneration and glial cell activation in 
the brain. 







Serine protease with trypsin- and 
chymotrypsin-like specificity. Cleaves 
complement C3. Has antibacterial 
activity against the Gram-negative 
Bacterium P. aeruginosa, antibacterial 
activity is inhibited by LPS from P. 
aeruginosa.  













Cysteine protease. Has dipeptidyl 
peptidase activity. Active against a broad 
range of dipeptide substrates composed 
of both polar and hydrophobic amino 
acids. Proline cannot occupy the P1 
position, and arginine cannot occupy the 
P2 position of the substrate. It can act as 
both an exopeptidase and an 
endopeptidase. Activates serine proteases 
such as elastase, cathepsin G and 
granzymes A and B. Can also activate 





















Cysteine protease. Key protease 
responsible for the removal of the 
invariant chain from MHC class II 
molecules. The bond-specificity of this 
proteinase is in part similar to the 
specifics of cathepsin L and cathepsin 
N. 







Closely involved in osteoclastic bone 
resorption and may participate partially 
in the disorder of bone remodeling. 
Displays potent end protease activity 
against fibrinogen at acid pH. May play 
an important role in extracellular 
matrix degradation. 







Essential for the overall degradation of 










218  It has a collagenolytic activity and 
participates in Collagen degradation. 






Aspartic acid protease and is active in 
intracellular protein breakdown. 
Involved in the pathogenesis of several 
diseases such as breast cancer and 
possibly Alzheimer’s disease. 
 
To find a selective probe for human cathepsin B, it is necessary to identify unique residues 
within a binding pocket of this protein compared to other members of the cathepsin family. 
Therefore, PDB structure (1HUC) was added to the multiple sequence alignment to limit the 
variable residues to those that are within mature CTB. The active site homology of human CTB 
and 1HUC (Cys108; His278, and Asn298) with seven members (cathepsin Z (CTZ); cathepsin L2 
(CTL2); cathepsin H (CTH); cathepsin C (CTC); cathepsin S (CTS); cathepsin K (CTK), and 
cathepsin L1 (CTL1)) of cathepsin family which was obtained from multiple sequence alignment 
51 
 
with CLUSTALX-2.1 software (Clustal: Multiple Sequence Alignment AUG,2012), is shown in 
Figure 9. Given the active site similarity between human CTB and other members of the cysteine 
cathepsin family, designing a probe specific to CTB is difficult.  
 
Figure 9. Section of multiple sequence alignment of human CTB and 1HUC with other members of the 
cathepsins family (same organism), obtained from. CLUSTALX-2.1 software (Clustal: Multiple 
Sequence Alignment AUG,2012). The red boxes show the homology of three active site residues of 
CTB (Cys (108), His (278), and Asn (298)) with seven members of the cathepsin family (CTZ, CTL2, 
CTH, CTC, CTS, CTK, and CTL1). The horizontal red box shows the positions of the human CTB and 
1HUC structure in the alignment. 
To reveal fully, strongly, weakly conserved residues and, the variable amino acid of the 
human CTB relative to other members of the cathepsin family, the multiple sequence alignment 
obtained with CLUSTALX-2.1 software (Clustal: Multiple Sequence Alignment AUG,2012) was 
analyzed further. According to multiple sequence alignment results obtained with CLUSTALX-
2.1 software (Clustal: Multiple Sequence Alignment AUG,2012) (Table 2), there were two fully 
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conserved residues (serine (83) and glycine(286), two strongly conserved residues (arginine (87) 
and threonine (125), and one weakly conserved residue (glycine (153) in human CTB compare to 
other members of cathepsin family. The variable residues which were obtained here would have 
led us to identify the unique residues in human CTB compare to others member of the cathepsin 
family. The position of these fully, strongly, and weakly conserved residues are shown in (Figure 
10). As shown in Table 3, CTB shows the highest percentage of identity scores with Cathepsin C 
and the lowest percentage of identity scores with Cathepsin G. The identity percentage was 
calculated between each member relative to human CTB. 
Table 2. Information obtained from multiple sequence alignment (CLUSTALX-2.1) of the amino acids of 
12 members of the cathepsins family as well as 1HUC structure (Clustal: Multiple Sequence Alignment 
AUG,2012). The results show the fully, strongly (amino acid alter to another amino acid with similar 
biochemical characteristics) and weakly conserved (amino acid alter to another amino acid with different 
biochemical characteristics) variable residues of CTB and 1HUC compared to the rest of the cathepsin 
family.  
Variable position 80-82, 84-86, 88-124, 126-152, 154-285, 287-333. 
fully conserved 83 (S), 286 (G) 
strongly conserved 87 (R), 125 (T).  
weakly conserved 153(G). 
 
 
Table 3. Information obtained from multiple sequence alignment (CLUSTALX-2.1) of the amino acids of 
the cathepsins family (Clustal: Multiple Sequence Alignment AUG,2012)., which used to identify which 
cathepsin is the most closely related to CTB. 
Cathepsin family members Identity% scores 
 
(CATB: CATZ) 17 
(CATB: CATL2) 17 
(CATB: CATH) 23 
(CATB: CATE) 6 
(CATB: CATG) 3 
(CATB: CATC) 25 
(CATB: CATS) 24 
(CATB: CATK) 19 
(CATB: CATL1) 20 
(CATB: CATL3) 6 





Figure 10. View of the parts of aligned multiple sequences of 12 members of the cathepsin family and 
1HUC structure by CLUSTALX-2.1 software (Clustal: Multiple Sequence Alignment AUG,2012), which 
indicates the fully, strongly and weakly conserved residues. The brown and red and yellow boxes are 
marked the fully, strongly and weakly conserved residues, respectively.  
 
From variable residues which are shown in (Table 2), those were selected which have 
different side chains that result in chemical properties diversity compared to the rest of the 
cathepsin family. According to the results which are shown in, Figure 11, we found seven unique 
residues (Glu115, Ser118, Glu132, Ser254, Arg281, Asn301, and Glu324) in human CTB 
compared to other members of cathepsin family. For example, glutamic acid at position 115 of the 
human cathepsin B is an acidic amino acid which can form an ionic bond, while most of the family 





Figure 11. Multiple sequence alignment of 12 members of the cathepsin family and 1HUC structure 
obtained using CLUSTALX-2.1 software (Clustal: Multiple Sequence Alignment AUG,2012). The 
vertical black boxes mark the unique residues in human CTB relative to other members of the cathepsin 
family, in terms of different biochemical characteristics. The horizontal black boxes show the positions of 
the human CTB and 1HUC structure in the alignment.  
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In addition to those variable residues mentioned above, we also checked the residues in the 
occluding loop of cathepsin B which is a unique feature of this protein. The presence of two 
adjacent histidines (basic amino acid) at position 189 and 190 which are located near the catalytic 
binding site of the CTB, could be a good target for probe binding. According to multiple sequence 
alignment with CLUSTALX-2.1, the rest of the family did not have any basic amino acids in those 
locations (Figure 12). Additionally, none of the cathepsin members in their entire amino acid 
sequence have two adjacent histidines except cathepsins H, S, C, and D. Cathepsin H has two 
adjacent histidine residues at positions 61 and 62 and cathepsin S at 26 and 27; however, both 
residues are located within the propeptide segment which is cleaved during enzyme maturation. 
Cathepsin C has two pairs adjacent histidine residues (366-367 and 389-390), while cathepsin D 
has two at positions 120 and 121, both of which are present in the mature enzymes. Further 
investigation is required to estimate the distance of these histidines from active sites of these 





Figure 12. Multiple sequence alignment of 12 members of the cathepsin family and 1HUC structure 
obtained with CLUSTALX-2.1 software (Clustal: Multiple Sequence Alignment AUG,2012). The 
location of two adjacent histidines at positions 189 and 190 in CTB compared to other members of the 
family is marked by a vertical red box. The horizontal red box shows the positions of the human 
CTB and 1HUC structure in the alignment. 
Variable residues that are unique in human CTB can be targeted as anchor amino acids for 
biding of designed probes if they are within a close distance (0.5 to 7 Å) (Angles, Arenas-Salinas 
et al. 2020) of the binding pocket of CTB; therefore, the next step would be mapping these residues 
on the 3D structure of CTB to assess their position within the binding pocket of CTB. 
3.3.4. Mapping Variable Residues onto the 3D Structure of CTB 
General information about five experimentally determined structures of CTB, as well as two 
experimentally determined structures of CTC and CTD, is shown in Table 4, which were obtained 




Table 4.  Information obtained from the RCSB PDB website (RCSB PDB 2018, OCT 30) about five of 
the experimentally determined structures for human CTB, as well as two experimentally determined 
structures of human CTC and CTD. 
PDB 
code 









1PBH Crystal structures of human pro-
cathepsin B at 3.2 and 3.3 Å 
resolution reveals the propeptide 
folds on the surface, shielding the 
active site of the enzyme from 
exposure to solvent.  (Turk, 






3PBH The crystal structure of the wild-
type human pro-cathepsin B at 
2.5 Å resolution reveals the native 
active site of a papain-like 
cysteine protease zymogen. 






1CSB Crystal structure of cathepsin B 
inhibited with CA030 at 2.0- Å 
resolution: This structure provides 
the basis for the design of specific 
epoxysuccinyl inhibitors. (Turk, 








3CBJ Displacement of the occluding 
loop by the parasite protein 
“chagasin” (act as a cysteine 
exopeptidase inhibitor) results 
from inefficient inhibition of 
human cathepsin B. Chagasin 
structure in complex with 
cathepsin B illustrating that the 
occluding loop is displaced to 
enable chagasin bind with its 
three loops and span the entire 
active site cleft. (Redzynia, 






1HUC The refined structure of human 
liver cathepsin B shows a 























3PDF Crystal structure of human 
cathepsin C inhibited with 
Cyanamide-Based Inhibitors 







1LYB Inhibited and native crystal 
structure of human cathepsin D 











In 1CSB structure, the ligand (EP0) with the molecular weight of 372.41 g/mol and the 
molecular formula (C17H28N2O7) (Figure 13) was visualized using VMD software (VMD 
APR,2008) to study the distance between the active site and unique residues of the human CTB 
and ligand.  
 
Figure 13. The chemical structure of ligand (EP0).  
 
To map the seven unique residues on the 3D structure of CTB and to find their distance 
from the ligand (EP0) within the binding pocket of this protein, the molecular graphics program 
VMD (VMD APR,2008) was used to visualize the 1CSB PDB file (Figure 14). Distances were 
measured between the alpha carbon (Cα) of all residues and atom C6, O1, and CD1 of the bound 




Figure 14. The 3D structure of CTB (PDB code 1CSB) which is visualized by VMD software (VMD 
APR,2008), the red, light and dark blue balls represent six unique residues that were identified by 
multiple sequence alignment (Glu115, Ser118, Glu132, Ser254, Arg281, and, Asn301). All these residues 
are located above 11 Å distance of ligand (EP0 (orange stick)). The position of unique residue Glu324, 
which is shown in a white circle, is located within close distance from the ligand (5.97 Å). 
According to Figure 14, all the unique residues for CTB which was identified for CTB 
through multiple sequence alignment with CLUSTALX-2 software are located in the far distance 
of the binding pocket of CTB (above 11 Å), except Glu324 which is located within close distance 
of the ligand EP0 (< 6 Å). Targeting Glu324, which is located within the close distance of the 
binding pocket of CTB as an anchor may rise the selectivity of ligands toward CTB over other 
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members of the cathepsin family, as the most of the cathepsin members have hydrophobic residue 
in that position.  
All the residues within 6 Å of the ligand were mapped to identify their names and positions. 
The identification of these residues would be useful since they could be targeted as an anchor for 
probes. The names and positions of all residues within 6 Å of the ligand (EP0) in the 1CSB 
structure was obtained from the VMD program (VMD APR,2008) are as follows: Gly102, Ser104, 
Cys105, Gly106, Cys108, Trp109, Asn151, Gly152, Gly153, His189, His190, Gly200, Glu201, 
Gly202, Val255, Met275, Gly276, Gly277, His278, Asn298, Trp300, and the unique residue: 







Figure 15. The 3D structure of CTB (PDB code 1CSB) with bound ligand (EP0 (yellow stick) after 
loading 1CSB under the VMD main window (VMD APR,2008). The red balls represent the residues 
located within 6 Å of the ligand. The list of these residues is as follows: Gly102, Ser104, Cys105, 
Gly106, Trp109, Asn151, Gly152, Gly153, His189, His190, Gly200, Glu201, Gly202, Val255, Met275, 
Gly276, Gly277, Trp300, and the unique residue: Glu324. The active site residues of human CTB marked 
as green balls: Cys108, His278, and Asn298. 
 
According to Figure 15, the two adjacent histidines (189 and 190) are within close distance 
from the active site of human CTB (less than 6 Å); however, the location of the two adjacent 
histidines (120 and 121) in human CTD (PDB code 1LYB) is more than 16 Å from the active site 
of this protein (Figure 16). Additionally, mapping two pairs of adjacent histidine (366-367 and 
62 
 
389-390) on the 3D structure of human CTC (PDB code 3PDF) reveals their distance from the 
active site of this protein which is > 17 Å (Figure 17). Distances were measured between the Cα 
of all residues. 
 
Figure 16. The 3D structure of cathepsin D (PDB code 1LYB) which is visualized by VMD software 
(VMD APR,2008), with the position of two active site residues (Asp97 and Asp295 (green balls)) and 





Figure 17. The 3D structure of cathepsin C (PDB code 3PDF) which is visualized by VMD software 
(VMD APR,2008), with the position of three active site residues (Cys258, His 405, and Asn427 (blue 
balls)) and their distance from two pairs of adjacent histidine at positions 366-367 and 389-390 (red 
balls). 
 
3.3.5. Computationally Identified Binding Interactions  
The software MOE was used to predict the binding interaction of the target probe 
CID8795ATTO680 with human CTB (PDB code 1HUC). All the residues numbers represented in 
this section are based on mature human CTB. As shown in Figure 18, the negatively charged 
sulfonate group of CID8795ATTO680 at the position P3 ionically interacts with two histidine 
residues (110 and 111) in the occluding loop of CTB (within the binding pocket of cathepsin B) 
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though its ATTO680 side in an acidic environment. This probe can participate in hydrogen bound 
through its ligand side with two glycines at positions 74 and 198 at the position P1. As shown in 
Figure 18, we do not expect any inhibitory activity of this probe against CTB due to not targeting 
any active site residues of this protein, although probe may interfere with substrate binding since 
it targets almost the same residues as Cbz-Arg-Arg-AMC (Figure 19) at both positions P1 and 
P3; therefore, this probe was subjected for inhibition assay with two commercial substrates 
(Chapter 6). From the amino acid sequence alignment results, in addition to CTB, cathepsins C 
and D also have two adjacent histidine residues in their mature protein. However, mapping these 
residues on the 3D structure of human CTD and CTC reveals they located in the far distance from 
the active site of these proteins (Figure 16 and Figure 17); therefore, CID8795ATTO680 would 




Figure 18. Predicted binding interaction between CID8795ATTO680 and CTB (PDB code 
1HUC). Diagram created with MOE (Molecular Operating Environment MOE March,2020). using the 
computationally generated structure of CID8795ATTO680 bound to CTB. P positions refer to positions 
in the substrate responsible for CTB recognition. 
To determined binding interaction between Cbz-Lys-Lys-PABA-DCMF and CTB, the 
docked structure (Daniel Tesolin, Private Communication) of the Cbz-Arg-Arg-AMC-CTB used 
as a surrogate. As shown in Figure 19, this substrate may bind to CTB at three main positions 
within P1, P2, and P3 pockets. At P1 position most cathepsins will accept a positively charged 
amino acid side chain such as lysine or arginine (Chowdhury, Moya et al. 2014), due to the 
presence of glutamic acid (122) within S1 pocket. However, at the P2 position, only CTB will 
accept a positively charged group, because of the presence of glutamic acid 245 within the S2 
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pocket. As mentioned in section 2.3.3 glutamic acid 245 (324 based on the CTB protein sequence) 
is unique to CTB as other members of the cathepsin family prefer amino acids with a hydrophobic 
side chain at this position. At P3 position, the ester group of the AMC dye seems to interact with 
histidine (111) through hydrogen-bonding with ion-dipole interactions.  
 
Figure 19. Predicted binding interaction between Cbz-Arg-Arg-AMC and CTB visualized with 
MOE (Molecular Operating Environment MOE March,2020). The structure of Cbz-Arg-Arg-AMC 
docked to CTB (PDB code 1HUC). P positions refer to positions in the substrate responsible for CTB 
recognition.  
.  
From the structure of Cbz-Arg-Arg-AMC docked to CTB, we were able to identify the 
possible binding interactions of our substrate-based probe. As shown in Figure 20, CTB prefers 
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positively charged residues at P1 and P2; however, other cathepsins prefer a large hydrophobic or 
aromatic amino acids at the P2 position. The presence of the PABA linker extends the substrate to 
potentially introduce interactions between the aromatic group at P3 with the S3 site and DCMF at 
P2´ with the S2´ respectively. 
 
Figure 20. The predicted binding interaction between Cbz-Lys-Lys-PABA-DCMF and CTB. P 
positions refer to positions in the substrate responsible for CTB recognition. 
 
3.4. Summary and Conclusions 
To develop a novel probe selective to cathepsin B, we studied this enzyme from nucleotide 
sequence to protein structure. We observed that cathepsin B shares common active site residues 
with more than half of the cysteine cathepsin family. The residues Glu115, Ser118, Glu132, 
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Ser254, Arg281, Asn301, and Glu324 in cathepsin B were found to be unique compared to other 
members of this family due to the presence of different side chain in their structures which lead to 
diversity in their chemical properties. Among all these unique residues only Glu324 are located 
within close distance of the catalytic site of human CTB (less than 6 Å). Glutamic acid is an amino 
acid that can form ionic bonds through the carboxylated group in its side chain with a positively 
charged species in acidic pH (~5.5). This residue can also act as a hydrogen bond acceptor and 
donor in its protonated form. From the analysis of docked structures and potential binding 
interaction, we expect this unique residue to increase the selectivity of Cbz-Lys-Lys-PABA-
DCMF toward CTB since most of the cathepsin family member prefer hydrophobic residue in that 
position.  
Two unique adjacent histidine residues which are located within 3.5 Å of the 
CID8795ATTO680, and targeted by ATTO680 of the probe, predict the probe selectivity toward 
CTB. Even though both cathepsin D and C have two adjacent histidine residues in their mature 
enzymes, the location of these histidine residues is more than ⁓16 Å of the active sites of both 




Chapter 4: Genetic Variation in Cathepsin B Gene (Homo sapiens) 
4.1. Introduction 
The 1,000 Genomes project (The International Genome Sample Resource 2008) was 
launched in 2008 to create an accurate catalog of human genetic variation. Galaxy (Galaxy 2019) 
is a web-based platform and an open-source tool for computational biological research and 
analyzing genomic data with a simplified interface for bioinformatics tools (Cock, Gruning et al. 
2013). In this project, the Lakehead Galaxy (Galaxy 2019) server has been used to access all the 
tools for analyzing, filtering, and converting the genomic data of the 1,000 Genomes database.  
Here, the first objective of using the 1,000 Genomes database is to identify SNPs, which are 
located on the CTSB gene (Homo sapiens), and identify which of these SNPs are missense variants 
located on or near the active site of the protein. Missense variants refer to the genetic alteration of 
the nucleotide sequence that alters the genetic code and leads to the incorporation of a different 
amino acid in the protein. These missense mutations may affect the binding of the probe to CTB 
in the individuals that carry them. The second propose of this project is to discover the common 
genetic diversity with frequencies of 50% or less in 1,000 Genomes populations. The final 
objective was identifying any mutations in this gene that may be associated with cancer. For 
investigating single nucleotide polymorphisms (SNPs) in the human gene encoding CTB, phase 3 
data from the 1,000 Genomes project have been used. This assembly used GRCh37/hg19 as a 
genome reference. However, more recently, GRCh38/hg38 has been used as a human reference 
genome (Devuyst 2015). This project allows access to the genome sequences of a large number of 
people, 2,504 individuals from 26 populations. Five populations were used in genetic analysis for 
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CTSB gene are as follows: African (AFR); American (AMR); East Asian (EAS); European (EUR), 
and South Asian (SAS) with 1018, 535, 617, 669 and 661 individuals respectively. 
4.2. Procedures and Materials  
4.2.1. Variant Identification in the 1,000 Genomes Data  
The aim of using the 1,000 Genomes project (The International Genome Sample Resource 
2008) is to investigate single nucleotide polymorphisms in a human CTSB gene in different 
populations; therefore, we need to inspect the frequency of each allele in the population. Allele 
frequency refers to the measure of the relative frequency of an allele in the population. In general, 
it is defined as a percentage or proportion, and it replicates the genetic diversity of a population. 
An allele frequency can be calculated as follows: the number of times that the target allele is 
recorded in a population divided by the total number of copies of the gene at that specific position 
in the population. To obtain allele frequency, the first step is to obtain genomic information as a 
Variant Call Format (VCF) and upload it to Galaxy (Galaxy 2019). 
Variant Call Format is the specified model of a text file (encoded format of single nucleotide 
variants) in bioinformatics to store marker and genotype data. Generally, VCF files contain three 
parts: meta-information lines; one header line, and data lines contain marker and genotype data 
(Danecek, Auton et al. 2011). In VCF files, the users can select the specific genomic positions 
depends on their needs. The genomic position code refers to the chromosome, the position number 
of a first and last nucleotide in the sequence. In this study, 8.11697472-11728207 indicates the 
location of the CTSB gene within the reference human genome GRCh37/hg19. The SNPs location 
is identified through its position within the reference genome. 
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Genomic data from the 1,000 Genomes project corresponding to the CTSB gene (Homo 
sapiens) was downloaded from the NCBI website as a VCF file with no filter (NCBI 2013, May). 
Afterward, the VCF file was uploaded to Lakehead’s Galaxy Server (Galaxy 2019). This VCF file 
contains all the allele frequencies of the CTSB gene. The next step was to filter SNPs to those 
located in the coding region of the CTSB gene and calculate genetic variation parameters. In 
general, rare mutations refer to variants that present in less than 1% of the population, whereas 
common mutations occur in more than 5% of the population (Gibson 2012). In Galaxy by using 
"VCFtools Filter" (Danecek, Auton et al. 2011) the SNPs were filtered in two following steps: i) 
minimum Minor Allele frequency (MAF) 0.001 and maximum MAF 0.01 for detecting rare 
polymorphisms which are presented in 1% or less of the population; and, ii) minimum MAF 0.01 
and maximum MAF 0.5 for studying common variants which are presented between 50% and 1% 
of the population. The "VCFtools Filter" is useful for summarizing data, performing calculations 
on data, filtering, and converting data into other file formats (Danecek, Auton et al. 2011). 
"VCFtools Filter" (Danecek, Auton et al. 2011) result represents in two output datasets: a "Log" 
folder which contains the information about the job itself and the number of polymorphic sites 
passing the filter and "VCFdataset" with only polymorphisms passing the MAF filter that the user 
selected. 
4.2.2. Identification of SNPs that Affect the Protein Sequence 
Generally, SNPs represent diversity in a DNA sequence, which can generate biological 
variations between people. Sometimes they have a direct role in the disease when they occur within 
a gene or in a regulatory region and have an impact on the phenotype (mutations). In general, 
though, they are mostly benign (Haraksingh and Snyder 2013). To identify any effect of SNPs on 
the sequence and the function of the protein, missense variants were investigated. The "SnpEff" 
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tool (Cingolani, Platts et al. 2012) implemented in Galaxy has been used to predict the effects of 
SNPs on the encoded protein and evaluate how many variants are classified as SNPs: deletion or 
insertion, missense, and nonsense. "SnpEff" is a tool for annotating and predicting the effect of the 
variant on genes (Cingolani, Platts et al. 2012). The parameters were used for running "SnpEff" 
are as follow; "Input and output formats" set as "VCF", the "Genome source" set as "Named on 
demand", the "GRCh37/hg19" selected under " SnpEff Genome Version Name", the 
"Upstream/Downstream length" set as "No upstream/downstream intervals (0 bases)", for 
"Annotation options", "Only use canonical transcripts" and "Use Classic Effect names and amino 
acid variant" were selected and, the "Text to prepend to chromosome name" set to "chr". "SnpEff" 
(Cingolani, Platts et al. 2012) generates two output datasets: one is the "Stats" file containing 
statistics information and the next one is "VCFdataset" including predicted effects for each SNP 
on the encoded CTB. Here, we needed to proceed with the "SnpEff" analysis twice: once with the 
VCF file filtered for MAF < 50%, and once with the VCF file filtered for MAF < 1%.  
4.2.3. Mapping SNPs in the Amino Acids Sequence and 3D Structure of CTB  
The amino acid sequence of the human CTB downloaded through the UniProt website 
(UniProtKB - P07858 (CATB_HUMAN)), 2018, May 25 #2614). Based on the "SnpEff" 
(Cingolani, Platts et al. 2012) output, all the common and rare mutations which were presented in 
(1% to 50%) and (1% or less) of the population, respectively, mapped on the human CTB amino 
acid sequence. Furthermore, the docked structure of CID8795ATTO680 (Daniel Tesolin, Private 
Communication) used for visualizing the location of these common and rare mutations on CTB by 




4.3.1. Variant Identification in the 1,000 Genomes Data 
According to "VCFtools Filter" (Danecek, Auton et al. 2011) results, 112 out of 1862 and 
370 out of 1598 variant sites in the CTSB gene were identified with MAF between (0.01 and 0.5) 
and (0.01 and 0.001), respectively. The variant filtering result with MAF between 0.01 and 0.5 
represents the common mutations that occur between 1% to 50% of the population. The variant 
filtering result with MAF between 0.001 and 0.01 represents the rare mutations that are carried by 
1% or less of the population.  
4.3.2. Identification of SNPs that Affect the Protein Sequence 
The "SnpEff" (Cingolani, Platts et al. 2012) predicts what effect each SNP is likely to have 
on the encoded CTB. In this study, the "SnpEff" analysis was carried out for two sets of analysis: 
one representing the effects of common SNPs on the coded CTB, and one for rare mutations which 
are present in 1% or less of the population.  
The "SnpEff" (Cingolani, Platts et al. 2012) results for common SNPs are as follows; 62.7% 
were missense SNPs and 37.3% silent variants out of total 100 SNPs. Only two variants cause 
amino acid substitutions: Ser53Gly, and Leu26Val, which are located on the propeptide of CTB. 
The propeptide of CTB (position at 18-79 amino acid) is cleaved during maturation and activation. 
Once cleaved, a propeptide generally has no independent biological function. In terms of 
association with diseases, out of the two common CTB mutations (Leu26Val and Ser53Gly) 
(Table 5), only Leu26Val reported being associate with a significant number of tropical chronic 




Table 5. The position of SNPs that cause amino acid changes in CTB found in MAF between 0.01 to 0.5 
for the entire population which has been studied in 1,000 Genomes databased These amino acid 
substitutions are located on the propeptide of CTB. 
 






Agc/Ggc p. Ser53Gly 0.057 
chr8: 11710888 (GRCh37.74) 
rs12338 
Ctg/Gtg p. Leu26Val 0.395 
 
The distribution of these SNPs in each continental population is shown in Figure 21. Based 
on the results, the highest percentage of allele frequency of (Leu26Val) belongs to the East Asian 
population (50%). Americans fit in the second level of allele frequency (39%), and African with 
33% in the last group. The Ser53Gly mutation is also observed in all continental populations except 
East Asian. For Ser53Gly mutation, the European population shows the highest allele frequency 
at 15%, which is almost double of American, while Asians and Africans have the lowest 
frequencies (below 4%) for this SNP. The frequency of Ser53Gly mutation through the population 

























































Figure 21. Population-based allele frequency of two variants associated with amino acid substitutions 
Ser53Gly and Leu26Val in the CTB protein.  
 
The "SnpEff " (Cingolani, Platts et al. 2012) result based on rare mutations (present in 1% or 
less of the population) shows that the total number of SNPs effects by functional class was 39.2% 
missense and 60.7% silent variants out of 127 SNPs. Here, eight SNPs caused amino acid changes 
(Gln334Pro, Asp317Asn, Asn246Thr, Lys237Glu, Ser235Asn, Pro91Leu, Thr75Ala, and 
Leu26Pro) of which five are located within the coding region of the mature human cathepsin B 
(Pro91Leu, Ser235Asn, Lys237Glu, Asn246Thr, and Asp317Asn). The exact position and 
substitutions of all eight amino acids are listed in Table 6. The distribution of these SNPs in 




Table 6. The position of SNPs that cause amino acid changes in CTB found in MAF between 
0.001 and 0.01 of the population.  






cAg/cCg p. Gln334Pro 0.006 
Chr8:11702705 (GRCh37.74) 
rs79487342 
Gat/Aat p. Asp317Asn 0.004 
Chr8:11704617 (GRCh37.74) 
rs114308907 
aAc/aCc p. Asn246Thr 0.004 
Chr8:11704645 (GRCh37.74) 
rs138489258 
Aag/Gag p. Lys237Glu 0.001 
Chr8:11704650 (GRCh37.74) 
rs17573 
aGc/aAc p. Ser235Asn 0.044 
Chr8:11708430 (GRCh37.74) 
rs11548596 
cCa/cTa p. Pro91Leu 0.003 
Chr8:11708479 (GRCh37.74) 
rs74996838 
Acc/Gcc P. Thr75Ala 0.005 
Chr8:11710887 (GRCh37.74) 
rs28605689 












































































































































AAG> GAG   Lys237Glu
 
Figure 22. Population-based allele frequency of five variants (located on mature CTB) associated with 
amino acid substitutions Pro91Leu, Ser235Asn, Lys237Glu, Asn246Thr, and Asp317Asn in the 
CTB protein.  
 
The highest percentage of the missense variant (Gln334Pro) and (Asp317Asn) belongs to 
East Asian 2.78% and 2.08%, respectively. For the missense variant (Asn246Thr), African people 
have the highest level of distribution (0.91%). East and South Asian populations illustrate 0% 
frequency for (Asn246Thr) mutation, which means they have no mutation in this location. African 
represents the highest percentage of allele frequency (16.57%) of the variant (Ser235Asn) 
meanwhile East and South Asian and European have no occurrence for this SNP (0%). Finally, 
South Asian has the most significant distribution (0.61%) for the variants (Lys237Glu) while other 
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populations have no change for this amino acid. The frequency of all the rare mutations mentioned 
here is not significant since 1% or less of all the population which have been studied here carry 
these variants. 
4.3.3. Mapping SNPs in the Amino Acids Sequence and 3D Structure of CTB 
The position of each common (MAF between 0.5 and 0.01) and rare (MAF between 0.01 
and 0.001) SNPs are marked in the amino acid sequence of human CTB in Figure 23. The two 
common variants are located on the propeptide portion of CTB. The mutations that may affect 
enzyme function are found in the mature and active CTB are Pro91Leu, Ser235Asn, Lys237Glu, 
Asn246Thr, and Asp317Asn. These mutations, however, are rare and are only present in 1% or 





Figure 23. The protein sequence of human CTB with marking SNPs. The red box indicates the 
propeptide of CTB (position at 18-79 amino acid) which is cleaved during enzyme maturation Mutations 
with MAF < 0.5 are highlighted in blue (Leu26Val and Ser53Gly). The rare variations with a MAF < 0.01 
that are located on the mature CTB identified by pink, meanwhile, those rare mutations which are not 
present in the mature CTB highlighted by orange color. Two mutations occur at position Leu26, common 
highlighted as blue and rare underlined by orange color. The red highlighted amino acids indicate the 
predicted binding site of the protein for the selected probes (Cbz-Lys-Lys-PABA-DCMF and 
CID8795ATTO680). Finally, the start and end positions of the mature protein are highlighted as green 
color. 
The amino acid substitutions were also mapped onto the three-dimensional structure of CTB 
(Figure 24). In this study, the fluorogenic substrate-based probes Cbz-Lys-Lys-PABA-AMC and 
Cbz-Lys-Lys-PABA-DCMF, and the non-reactive probe CID8795ATTO680 (Figure 24) were 
hypothesized to bind to CTB by targeting amino acids: Asn151, Gly152, Gly153, His189, His190, 
Gly200, Glu201, Val255, Met275, Gly276, Gly277, His278, Trp300, and Glu324 (see chapter 3). 
Therefore, we investigate the mutations in the predicted anchor amino acids in CTB for these 
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probes. Distances were measured between the Cα of all residues and atom Z of the bound ligand 
(CID8795ATTO680).  
 
Figure 24. View of docked structure of CID8795ATTO680 (Daniel Tesolin, Private Communication) 
with mapping residues within 3.5 Å of the probe by VMD software (VMD APR,2008). The red ribbons 
show the 1HUC carbon alpha trace. The probe is shown in blue. Yellow represents the residues within 3.5 
Å of the CID8795ATTO680. The name and position of these amino acids are as follows: Gly153, His189, 
His190, Gly200, Glu201, Val255, Met275, Gly276, Gly277, His278, Trp300, and Glu324. White 
represents the three active site residues (Cys108, His278, and Asn298) of human CTB. Green shows the 
positions of rare mutations on this structure which are located above 20 Å from the binding pocket of 
CTB. 
 
Mapping rare amino acid substitutions on the three-dimensional structure of human CTB as 
visualized with VMD (VMD APR,2008) shows that these amino acid substitutions may not affect 




4.4. Summary and Conclusions 
In this section, by using the 1,000 Genomes database and software implemented at 
Lakehead's Galaxy server, we were able to identify SNPs located in the coding region of the CTSB 
gene. SNPs were classified into two groups: rare (MAF 0.01 to 0.001) and common (MAF 0.5 to 
0.01) mutations. Here, our focus was on binding site residues of CTB for our probes. As described 
above, the analysis of genomic data did not identify the presence of mutations at these residues. 
All the SNPs, identified in this study, were mapped onto the CTB amino acid sequence and 3D 
structure of this protein to identify their location on this protein. The two common mutations which 
were found in 1% to 50% of the population are present on the proenzyme but, not the mature 
enzyme. These common SNPs cause the amino acid substitutions Ser53Gly (⁓ 6%) and Leu26Val 
(⁓ 39%) within the entire 1,000 Genomes database populations. CTSB polymorphism (Leu26Val) 
has been associated with pancreatic cancer (Mahurkar, Idris et al. 2006, HGMD 2020, June). 
Additionally, we found eight rare mutations in 1% or less of the population, five of which were 
located on the mature cathepsin B (Pro91Leu, Ser235Asn, Lys237Glu, Asn246Thr, and 
Asp317Asn). These rare variants were not located within the binding site of the protein and there 
were no diseases or conditions that have been reported as associated with them.  
In summary, there is no expected effect of these SNPs on the CTB/probe interactions; 
therefore, these mapping results suggest no differences in probe recognition is expected within the 




Chapter 5: Synthesis and Characterization of Fluorescent Probes  
5.1. Introduction  
Fluorescent probes have become indispensable tools for chemists and biologists to study the 
biological activities of proteins and enzymes in living cells and animals (Chen, Pradhan et al. 
2012). They provide visual information with high spatial resolution, and probes with NIR emission 
are preferable for in vivo imaging because of the low fluorescent interference due to the 
autofluorescence of cells and tissues due to natural compounds. Compared to conventional 
fluorophores that are excited at low wavelengths, NIR fluorescent probes can provide imaging 
data in deeper tissues due to their longer excitation wavelengths. Indeed, the NIR excitation and 
emission range results in less damage to biological samples than the shorter wavelengths (Celli, 
Spring et al. 2010, Guo, Park et al. 2014). 
5.1.1. Selection of NIR Probe Candidate 
For detecting overexpression of CTB in aggressive and invasive cancers, designing 
fluorogenic probes that have high affinity and selectivity is required. To accomplish this, probe 
molecules can be inherently fluorescent or comprised of a potent targeting moiety labeled with a 
fluorescent dye that binds to the enzyme. A total of 14,862 compounds were constructed in 
Kamstra and et al., and screened against CTB intending to identify non-reactive probes with near-
infrared (NIR) emission (Kamstra, Dadgar et al. 2014). From this library, seven ligands were 
selected for conjugation. General information about these seven potential ligands is shown in 




Table 7. Lead probe compounds discovered computationally (Daniel Tesolin, Private Communication) 
(Molport 2018, November 16).  
PubChem 
CID 













[4.3.1.1 < 3,8 >] undec-9-
ylidene]az amethyl} 
carboxamide 




















329.37 C16H15N3O3S Enamine 
(T5257017) 
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Ligands in this library are novel and designed for straightforward synthesis. Each compound 
is commercially available, and, in most cases, the ligands bear an amino-group (Table 8) that can 
be converted into a fluorescent NIR probe by conjugation to commercially available ATTO680 
dye with its N-hydroxysuccinimide (NHS)-ester group (amino-reactive) forming a stable amide 
linkage.  

























NHS-esters are preferable for the labeling process for four main reasons: 1) NHS-esters have 
high specificity towards the primary amines group; 2) the resulting amide is a very stable linkage 
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(Sameiro and Goncalves 2009), 3) ATTO680 is a hydrophilic dye which allows better functionality 
in vitro and in vivo (Buschmann, Weston et al. 2003), 4) it has a fluorescence lifetime at 3.04 ns 
which indicates better differentiation in FP assay between its free form and bound form (Hughes, 
Rawle et al. 2014). The chemical structures of the ATTO680 fluorescent dyes used in this study 




Figure 25. The chemical structure of ATTO 680 NHS-ester. The red circle indicates the site of 
conjugation. 
 
According to the reaction in Scheme 2, R1-NH2 is the ligand, and R2-NHS-ester is the 
commercially available ATTO 680 dye. In this study, the synthesis of the fluorescent conjugates 
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was performed in collaboration with Dr. Morshed Chowdhury from Dr. Phenix’s group. Seven 
candidates were identified as potential ligands of CTB and were used as starting material for 
conjugation chemistry employing an ATTO 680 NHS-ester dye. As described above, all seven 
candidates had a primary amino group that should attack the ATTO 680 NHS-ester forming an 
amide as the conjugation functional group. Of note, some of the ligands shown above have a 
primary amine that is attached to an aromatic ring (e.g. CID2434131, CID4917705, CID667134). 
Therefore, the lone pair of electrons on nitrogen is delocalized into the  system thus reducing the 
reactivity of the amine making conjugation with the ATTO680 more difficult compared to the 
ligands bearing a primary amine. 
 
Scheme 2. Chemical reaction scheme of ligands (Table 8) with an amino group and ATTO 680 
NHS-ester dye. Where R1-NH2 is the ligand attached to the amine group, and R2-NHS-ester is ATTO 680 
dye bound to the N-hydroxysuccinimide group. 
 
5.1.2. Selection of Substrate-Based Fluorescent Probe 
 Previously, Dr. Phenix’s group designed and synthesized prodrug inspired substrate-based 
fluorogenic probes selective to CTB (Chowdhury, Moya et al. 2014). Each substrate consisted of 
an N-carbobenzyloxy (Cbz) protected dipeptide (Cbz-phenylalanyl-lysine and Cbz-lysine-lysine) 
conjugated to the prodrug linker p-Aminobenzyl alcohol (PABA) and 7-Amino-4-methylcoumarin 
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(AMC) as a fluorescent reporter group. They found that treating the fluorogenic peptides Cbz-Phe-
Lys-PABA-AMC (kcat/KM of 6.1 ± 7 mM–1 s–1) and Cbz-Lys-Lys-PABA-AMC (231 ± 70 mM–1 
s–1) with CTB led to the efficient release of PABA and spontaneous immolation of the linker to 
liberate AMC as the fluorescent reporter. Importantly, the intact peptides had little to no 
fluorescence, and the enzymatic reactions could be monitored by measuring the fluorescence 
intensity of the released AMC (λex = 380 nm: λem = 460 nm). A series of detailed biological 
experiments showed that Cbz-Lys-Lys-PABA-AMC was selective to CTB in cancer cell lysates 
and its hydrolysis could be detected in living cells monitored by confocal microscopy. In contrast, 
Cbz-Phe-Lys-PABA-AMC displays low specificity and high toxicity in live-cell fluorescence 
microscopy studies (Chowdhury, Moya et al. 2014). An additional limitation was that the 
substrate-based probes employed AMC (λex = 380 nm: λem = 460 nm) as a fluorescent reporter 
group. At these excitation and emission wavelengths, live cells have high endogenous fluorescence 
due to natural fluorescent species found in cells (e.g., auto-fluorescence). More sensitive 
fluorescence imaging studies can be accomplished in live cells by using fluorophores with longer 
wavelengths or by incorporating a radioactive reporter. To address these shortcomings, a new 
substrate-based probe was designed using a fluorescent reporter group with longer excitation and 
emission wavelengths as well as a dye that remains fluorescent over a broader pH range. Molecular 
docking was used (results not shown here) to select fluorophores that are expected to maintain or 
improve binding affinity to CTB. To improve the fluorescent profile of the new probe at low pH, 
one of the fluorescein derivatives (2’, 7’-dichloro-6’-methoxy-fluorescein (DCMF with λex = 480 
nm and λem = 522 nm)) has been selected. DCMF has been used previously for reporting on 
enzymatic activity in the lysosome of cells (Mugherli, Burchak et al. 2006, Harlan, Lusk et al. 
2016). Also, its maximum emission wavelength is well above the cellular background. The 
89 
 
chemical structures of the DCMF fluorescent dyes used in this study are displayed in Figure 26. 
In this figure, the reactive group targeted for conjugation is indicated by red circles. 
 
Figure 26. The chemical composition of 2’, 7’-dichloro -fluorescein. The red circles indicate sites of 
conjugation. 
5.2. Procedures and Materials  
5.2.1. Synthesis of the NIR Probe  
Conjugation is the process by which the dye and a compound of interest react to form a 
single chemical entity. The chemical conditions used for each conjugation process depends on the 
functional groups present on the reactant and the dye structure (Feixas, Matito et al. 2011).  
To synthesize the dye-labeled conjugates, the dye was purchased with an activated ester 
utilizing N-hydroxysuccinimide as a leaving group. Nucleophilic attack by the primary amine of 
the binding ligand would generate the fluorescent probe (as an amide) required for testing. For the 
conjugation reactions to be successful, dry DMF was used since water may hydrolyze the N-
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hydroxysuccinimide ester leading to poor yields. Triethylamine was added as a base to neutralize 
the protons produced during the conjugation reaction. The reaction mixture was stirred at 0 ºC for 
30 min and then at room temperature overnight. After overnight incubation, water was added to 
the reaction, and the mixture was extracted with ethyl acetate. The aqueous layer was separated 
and freeze-dried to get the title compound as a dark blue solid. Since CID8795ATTO680 and 
CID535684ATTO680 were obtained in low mg amounts, NMR was not done for these probes. For 
these products after running TLC, column chromatography was used for purification of the 
products. After purification, all spots on the TLC were subjected to TLC-mass spectrometry using 
the Advion Expression CMS, which confirmed the molecular weight of CID8795ATTO680 at 
636.31 g/mol and CID535684ATTO680 at 661.30 g/mol as expected. Unexpectedly, none of the 
synthesized probes were soluble in the water; therefore, DMSO used for making the stock solution 
for CID8795ATTO680 and methanol used as a solvent for CID535684ATTO680.  
 
5.2.2. Synthesis of the Fluorescent Substrate  
2’, 7’-Dichlorofluorescein (1) 
2’, 7’-Dichlorofluorescein was prepared following literature procedures (Mugherli, Burchak 
et al. 2006). 
Characterization of the dye matches previously published NMR and mass spectra data. This 
section is done by Dr. Morshed Chowdhury from Dr. Phenix's group. 
2’, 7’-Dichloro-6’-methoxy-fluorescein (2) 
MeI (1.33 g, 9.37 mmol) was added to the mixture of 1 (1.5 g, 3.74 mmol) and K2CO3 (1.3 
g, 9.37 mmol) in 15 ml of DMF at room temperature. After stirring for 24 hours, the reaction 
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mixture was quenched with H2O and solvents removed under reduced pressure. To this residue 
was added 30 mL of an aqueous solution of 10% NaOH and 60 mL of acetone. This mixture was 
subsequently refluxed for 1 hour at 60°C. The solution was cooled to room temperature, then 
diluted with 100 mL of EtOAc. Dilute HCl was added to acidify the mixture to approximately pH 
= 3 and then extracted the organic layer three times with 100 mL of EtOAc. The organic layers 
were combined and washed with brine, dried with sodium sulfate, and filtered. The solvent 
removed under vacuum, and the resulting solid was purified using silica gel chromatography (2:1 
EtOAc: Hexanes with 0.1% AcOH) to get 2 (853 mg, 55%) as an orange solid. 1H NMR (500 
MHz, CDCl3) δ 8.07 (d, J = 7.4 Hz, 1H), 7.70 (m, 2H), 7.17 (d, J = 7.5 Hz, 1H), 6.92 (s, 1H), 6.81 
(d, J = 4.6 Hz, 1H), 6.77-6.68 (m, 2H), 3.95 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.08, 156.66, 
152.09, 150.97, 150.77, 135.55, 130.34, 128.70, 128.07, 126.34, 125.47, 123.86, 118.27, 111.23, 
108.81, 104.13, 103.56, 100.39, 56.48. LRMS (ESI): m/z Calcd for [C21H12Cl2O5 + Na] +: 436.99; 
found: 437.00. 
 
Cbz-Lys-N-ε-BOC-Lys-N-ε-BOC-PAB-2’, 7’-Dichloro-6’-methoxy-fluorescein (4) 
Compound 2 (257 mg, 0.168 mmol) was added to a mixture of 3 (400 mg, 0.515 mmol) and Ag2O 
(143 mg, 0.618 mmol) in 10 mL of benzene. The mixture was refluxed in the dark for 24 hours. 
After quenching the reaction with 50 mL of water the mixture was passed through filter paper into 
a separatory funnel. The filter paper was washed with EtOAc and added to the same separatory 
funnel. 100 mL EtOAc was added, and the aqueous phase was extracted three additional times 
with 50 mL of EtOAc. The organic layers were combined then washed with brine (saturated NaCl), 
dried with Na2SO4, filtered, and concentrated under vacuum. Silica gel chromatography (2:1 
EtOAc: Hexanes → 5:1 EtOAc Hexanes) yielded compound 4 (130 mg, 23%) as a light orange 
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solid. 4: 1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 7.4 Hz, 1H), 7.78-7.69 (m, 2H), 7.63 (d, J = 
8.6 Hz, 2H), 7.39 (d, J = 8.6 Hz, 2H), 7.35-7.23 (m, 5H), 7.17 (d, J = 7.4 Hz, 1H), 6.95 (s, 1H), 
6.87 (s, 1H), 6.71 (s, 1H), 6.67 (s, 1H), 5.11 (s, 2H), 5.09 (s, 2H), 4.52-4.46 (m, 1H), 4.18-4.13 
(m, 1H), 3.86 (s, 3H), 3.07-2.96 (m, 4H), 1.94-1.60 (m, 4H), 1.54-1.37 (m, 26H). LRMS (ESI): 
m/z Calcd for [C58H65Cl2N5O13 + Na] +: 1132.38; found: 1132.39. 
Cbz-Lys-Lys-PAB-2’, 7’-Dichloro-6’-methoxy-fluorescein 2TFA. (-5-) 
Compound 4 (100 mg, 0.09 mmol) was added to a dry flask and cooled to 0°C using an ice 
bath. In a separate container, a 1:1 TFA: CH2Cl2 (anhydrous) stock was made and cooled to 0°C. 
Using a syringe, 0.5 mL of 1:1 TFA: CH2Cl2 stock was added to the flask dropwise while stirring 
and maintaining a temperature of 0°C for 10 minutes. After this time, 5 mL of diethyl ether was 
added to precipitate the dipeptide. The mixture was transferred to a 15 ml Eppendorf tube and 
centrifuged at 10000 g for 1 minute at 4°C. The diethyl ether was subsequently discarded while 
keeping the precipitate intact. The precipitate was re-suspended in 5 mL of diethyl ether, and the 
centrifugation steps, including washing with ether, was repeated two more times. The final residue 
was then purified on a Waters Sep-Pak® tC18 plus cartridge using 2% ACN: H2O as the eluent. 
The fractions containing the desired compound were then frozen and freeze-dried to yield 
compound 5 (11 mg, 11%) obtained as a faint orange solid. The NMR result for the new substrate 
is as follows: (2:1 EtOAc: Hexanes with 0.1% AcOH) to get 2 (853 mg, 55%) as an orange solid. 
5:1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 7.4 Hz, 1H); 7.92-7.54 (m, 4H); 7.44 (d, J = 7.6 Hz, 
1H); 7.41-7.27 (m, 6H), 7.21 (d, J = 7.6 Hz, 1H); 6.97-6.92 (m, 1H); 6.91-6.85 (m, 1H); 6.78-6.73 
(m, 1H); 6.73-6.65 (m, 1H); 5.15 (s, 2H), 5.12 (s, 2H); 4.58-4.50 (m, 1H); 4.21-4.11 (m, 1H); 3.86 
(s, 3H); 2.99-2.84 (m, 4H), and 2.01-1.44 (m, 12H). LRMS (ESI): m/z Calcd for [C48H49Cl2N5O9 
+ Na] +: 932.28, found: 932.29. 
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As described above, Cbz-Lys-Lys-PABA-DCMF was synthesized in 5 chemical steps which 
are shown below in Scheme 3. 
 
 
Scheme 3: Fluorophore synthesis and peptide coupling. (a) i) MeI, K2CO3, DMF, rt; ii) 10% NaOH(aq), 
acetone, reflux; iii) 0.1 M HCl(aq), 55%; (b) 3, Ag2O, benzene, reflux, 23%; (c) TFA, CH2Cl2 at 0°C, 11%. 
 
5.2.3. Spectrophotometric Characterization 
The emission and excitation of all the ligands at 100 µM, the NIR conjugates at 40 µM, and 
dye (DCMF) at 1 µM were initially measured prior to any binding experiments with the enzymes. 
Maximum absorbance, emission, and excitation spectra were determined for all fluorescent 
compounds at 37°C using a Synergy 4™ plate reader (Biotek Inc). The absorbance spectra were 
taken from 300 nm to 750 nm in 5 nm increments. For the emission spectra, the excitation 
wavelength maxima were chosen for each compound monitoring emission at 400 nm to 800 nm 
in 5 nm increments. Four buffers have been used in these experiments; CTB reaction buffer, Tris 
at 50 mM, MES at 50 mM, and acetate buffer at 50 mM. For ligands, the commercial CTB reaction 
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buffer at pH 7.2, for CID8795ATTO680 and CID535684ATTO680 as well as CTB reaction buffer, 
Tris (pH 7) and MES (pH 4) were used. Finally, for DCMF acetate buffer at pH 5.5 was used. For 
CID8795ATTO680 and CID535684ATTO680 a two-fold serial dilution with a starting 
concentration at 0.195 to 200 µM was used for measuring anisotropy and fluorescence intensity 
assays at zero-time point, at pH 7.2 and 37ºC.  
5.3. Results 
5.3.1. Synthesis and Conjugation of Selected Hits  
Seven ligands that were selected from a computational screening (Kamstra, Dadgar et al. 
2014) were subjected to conjugation chemistry with ATTO 680 NHS-ester (CID2434131, 
CID5939530, CID667134, CID1256741, CID2999504, CID8795, and CID535684). As expected, 
CID8795 and CID535684 reacted smoothly with the ATTO dye resulting in novel compounds 
named CID8795ATTO680 (Figure 27) and CID535684ATTO680 (Figure 28), respectively. 
Unfortunately, the fluorescent conjugates were not produced by the conjugation chemistry for 
CID2434131, CID5939530, CID667134, CID1256741, and CID2999504. This is likely due to the 
low reactivity of the nitrogen atom in some of these ligands due to the delocalization of the lone 




Figure 27.  The chemical structure of the CID8795ATTO680. 
 




5.3.2. An Improved Substrate-Based Fluorescent Probe for CTB 
In this work, we employed the same scaffold previously reported (Cbz-Lys-Lys-PABA) 
(Chowdhury, Moya et al. 2014) but with DCMF as a fluorescent reporter.  
The 2’,7’- Dichlorofluorescein (1) was methylated in DMF to form a methyl ester and 
methyl ether to produce compound 1 (compound was not isolated). The ester of compound 1 was 
then hydrolyzed using 10% NaOH to reform the lactone ring resulting in compound 2 in low yield. 
This fluorophore was then coupled with Cbz-Lys-N-ε-BOC-Lys-N-ε-BOC-PAB-Br (3), using Ag2O 
in a non-polar solvent to obtain peptide 4. Compound 3 was already prepared and available in the 
Phenix lab. Boc (Tert-butoxy carbonyl protecting group) deprotection with Trifluoroacetic acid 
(TFA) yielded the final compound 5 (Scheme 3) ( (UniProtKB - P07858 (CATB_HUMAN)) with 




5.3.3. Spectrophotometric Characterization 
To determine if the ligands identified by Tesolin, had inherent fluorescence, excitation, and 
emission spectra were measured for all ligands; CID2434131, CID5939530, CID667134, 
CID1256741, CID2999504, CID8795, and CID535684. None of these ligands showed any 
inherent fluorescence in their spectrophotometric characterization. 
The conjugate CID8795ATTO680 (Figure 29) had an excitation maximum at 675 nm and 
an emission maximum at 705 nm (Figure 29 A) with emission increasing linearly with 
concentration from 0.195 µM to 200 µM (Figure 29 B). Conjugate CID535684ATTO680 (Figure 
30) had a maximum excitation at 675 nm and emission at 690 nm (Figure 30 A); the fluorescence 
intensity rises linearly with the concentration from 0.195 µM until 30 µM (Figure 30 B). However, 
linearity was not maintained above 30 µM of the conjugate CID535684ATTO680. it could be due 
to aggregation of the conjugate or reabsorption of emitted photons by a ground-state molecule that 
caused quenching. 
Fluorescence polarization and anisotropy of both NIR probes were measured for a two-fold 
serial dilution with a starting concentration at 0.195 µM and end concentration at 200 µM. The 
objective was to identify a workable concentration range of the probes for further experiments. 
Two buffers, Tris pH 7 (Figure 29 C) and MES pH 4 (Figure 29 D) were selected for 
CID8795ATTO680 to observe the behavior of the probe at different pHs. For 
CID535684ATTO680; Tris pH 7 (Figure 30 C) and CTB reaction buffer pH 7.2 (Figure 30 D) 
were selected based on preliminary experiments which confirmed the better change in anisotropy 
for this probe in this range of pHs. Fluorescence polarization results of the probes did not vary 
significantly over the concentrations range tested at zero-time point; therefore, we chose 1, 10, and 
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25 µM for further assays reported in chapter 6. Further, no change in polarization was observed 
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Figure 29. Fluorescence profile of CID8795ATTO680. A) Blank-discounted excitation and emission 
spectra of CID8795ATTO680 at 40 µM, pH 7, showing maximum excitation and emission at 675 and 705 
nm respectively. B) Fluorescence intensity measurement (at 0-time point) of different concentrations of 
CID8795ATTO680 (two-fold serial dilution with a starting concentration at 0.195 to 200 µM), which is 
increased linearly with the increase of the conjugate concentration. Linear regression was performed 
using Prism 5 software (Prism 2018, November 16) with the R-squared (R2) at 0.99. FP results presented 
in (C) and (D) refer to the log concentrations of CID8795ATTO680 at 60 minutes and pH 7 (C) and 4 (D) 
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Figure 30. Fluorescence profile of CID535684ATTO680. A) Blank-discounted excitation and emission 
spectra of the CID535684ATTO680 (40 µM) at 675 and 690 nm respectively at pH 7. B) Fluorescence 
intensity measurement (at the 0-time point) of the different concentrations of CID535684ATTO680(a 
two-fold serial dilution with a starting concentration at 0.195 to 200 µM), which is increased linearly to 
the increase of the conjugate concentration, the linear regression fit has been applied by using Prism 5 
software (Prism 2018, November 16) with the R2 at 0.99, non-linearity was observed at concentrations 
above 30 µM. FP results represented in (C) and (D) refer to the log concentrations of 
CID535684ATTO680 at pH 7 and 7.2 at the 0-time point, respectively. All assays were carried out at 37º 
temperature. 
According to the excitation and emission spectra of both NIR conjugates, the relative 
intensity (arbitrary units (a.u.)) values were very low ranging (zero to 30 a.u.) for 
CID8795ATTO680 and (zero to 300 a.u.) for CID535684ATTO680 at 40 µM, which could be a 
sign of self-quenching.  
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The chemical structure of Cbz-Lys-Lys-PABA-DCMF is presented in Figure 31. The 
spectrophotometric characterization of DCMF indicates the product of the enzymatic cleavage has 
maximum fluorescence excitation (λex = 480 nm) and emission (λem = 522 nm) (Figure 32).  
 
Figure 31. The chemical structure of the Cbz-Lys-Lys-PABA-DCMF.  
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5.4. Summary and Conclusions 
Three fluorescent probes (CID8795ATTO680, CID535684ATTO680, and Z-Lys-Lys-
PABA-DCMF) were successfully synthesized. For the non-reactive probes, seven potential CTB 
ligands were subjected to conjugation chemistry with ATTO 680 NHS-ester. Two of them 
(CID8795ATTO680 and CID535684ATTO680) were successfully prepared and used in further 
binding experiments. Both non-reactive probes were fluorescent after conjugation with the ATTO 
dye, thus not requiring CTB for activation. A novel substrate-based probe was prepared using the 
same Z-Lys-Lys dipeptide scaffold as Dr. Phenix’s group previously reported, but with DCMF as 
a fluorophore.  
The spectrophotometry results of CID8795ATTO680 and CID535684ATTO680 indicate 
the excitation and emission wavelengths of 675 nm and 705 nm, 675 nm, and 690 nm, respectively, 
although the RFU values were too low and could be a proof of self-quenching for both probes. The 
excitation and emission wavelengths of DCMF is 480 nm and 522 nm, respectively. As expected, 
the spectrophotometric characterization of Z-Lys-Lys-PABA-DCMF indicated no fluorescence 




Chapter 6: Evaluation of Binding Interaction of CID8795ATTO680 and 
CID535684ATTO680 to CTB 
6.1. Introduction  
Recently, there has been tremendous progress in the design of NIR probes for imaging 
enzyme expression and activity in complex biological samples including cells and animals. We 
synthesized two novels NIR fluorescent probes for CTB: CID8795ATTO680 and 
CID535684ATTO680, which are fluorescent and intended to bind reversibly to CTB. In this 
chapter, we will evaluate the binding interactions of these non-reactive probes to CTB using 
competitive inhibition, fluorescence polarization, and fluorescence intensity measurements 
(Appendix section 2). In this study, anisotropy measured due to observing better prediction of the 
binding interaction between ATTO 680 conjugates to CTB by taking into account the total 
intensity of the samples.  
6.2. Procedures and Materials  
6.2.1. Evaluating the Inhibition Activity of the Ligands on CTB 
Experiments were performed to determine if the ligands had inhibitory activity towards CTB 
using an inhibitor screening kit (Sigma Aldrich, Catalog number: MAK200). Each kit contained 
CTB reaction buffer at pH 7.2, CTB reagent, human recombinant cathepsin B, CTB substrate, 
Acetyl-Arg-Arg-7-Amino-4-trifluoromethyl coumarin (Ac-Arg-Arg-AFC) (Figure 33), and a 




Figure 33. The chemical structure of Acetyl-Arg-Arg-7-Amino-4-trifluoromethyl coumarin.  
 
Figure 34. The chemical structure of Phe-Phe-Fluoromethyl ketone. 
The assay concentrations of CTB (0.5 µM), peptide substrate (200 µM), and the control 
inhibitor F-F-FMK (10 µM) were used as recommended by the manufacturer. Ligands were tested 
for CTB inhibition at final ligand concentrations of 100, 10, and 1 μM. Any inhibitory effect 
attributed to solvent (DMSO or ethanol) was accounted for by separate control reactions 
containing solvent instead of the test compound – with and without CTB. Reactions were carried 
out in the CTB reaction buffer at pH 7.2. The final reaction volumes were 100 μL, replicates twice 
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and each assay was repeated twice. Fluorescence was measured using a Synergy 4™ microplate 
reader in kinetic mode for 60 minutes in 1-minute intervals, with excitation and emission 
wavelengths at 400 nm and 505 nm, respectively. All reactions proceeded at body temperature 
(37°C). The slope of the linear portion of the reaction progression curve (time versus fluorescence 
intensity) was used to calculate initial velocity (RFU/min) with and without the presence of the 
ligand at 100, 10, and 1 µM, as well as, the average of the last seven minutes of the reaction 
progression curves for evaluating the inhibition activity of the ligands on the total amount of AFC 
formation. All samples were blank (100 µl of the CTB reaction buffer) discounted. The AFC dye 
was not available to construct a standard curve. The statistical difference between samples (CTB 
and Ac-Arg-Arg-AFC with different concentrations of ligands or inhibitor) and baseline (CTB and 
Ac-Arg-Arg-AFC) was estimated by ANOVA with post-hoc Dunnett’s multiple comparison test 
using Prism 5 software (Prism 2018, November 16). A p < 0.05 was considered significant.  
6.2.2. Evaluating the Inhibition Activity of the Two NIR Probes on CTB 
To evaluate the inhibitory activity of two new probes (CID8795ATTO680 and 
CID535684ATTO680) on CTB, the same inhibition procedure as for the ligands was repeated. All 
reagents used in these assays were at the same concentrations as those used for ligands inhibition 
assay (6.2.1 section). The slope of the linear portion of the progression curve was used to calculate 
initial velocity (RFU/min) in the absence and the presence of probe at 25, 10, and 1 µM. The 
average of the last seven minutes of the progression curve was also calculated and used to assess 
the effect of the non-reactive probes on the total amount of AFC formation. All the samples were 
blank (100 µl of the CTB reaction buffer) discounted. The statistical difference between samples 
(CTB, Ac-Arg-Arg-AFC, and different concentrations of non-reactive probes or inhibitor) and 
baseline (CTB and Ac-Arg-Arg-AFC) were measured by ANOVA with post-hoc Dunnett’s 
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multiple comparison test using Prism 5 software (Prism 2018, November 16). A p < 0.05 was 
considered significant.  
To confirm inhibitory activity, a commercially available colorimetric CTB substrate, Z-Arg-
Arg-pNA, was used in a similar inhibition screening assay to test CID8795ATTO680. A 
colorimetric substrate was chosen to minimize any potential interference from a fluorescent 
substrate with CID8795ATTO680. The second purpose of selecting this substrate was to test the 
probe at a lower pH. The Ac-RR-AFC substrate is more active at pH 7.2 than at pH 5.5 according 
to the manufacturer’s instructions. However, a CTB probe should ideally work at the lower pH of 
the lysosome, for which the colorimetric substrate Z-Arg-Arg-pNA is adequate.  Therefore, the 
colorimetric assay was performed at pH 5.5 in the acetated buffer corresponding to the pH of the 
biological system.  
Absorbance at 410 nm was read on a Synergy 4™ plate reader (Biotek Inc) in kinetic mode 
every 1 minute for 60 minutes at 37°C. Seven concentrations of the serial dilution of pNA, 10-fold 
(1 to 1x10-6 mM) in assay buffer were conducted to construct a standard curve. The slope of the 
standard curve was used to evaluate the formation of pNA from the hydrolysis of Z-Arg-Arg-pNA 
under the presence of CTB. The colorimetric substrate was assayed at 200 µM against 0.01 µM 
CTB, in the absence and the presence of the CID8795ATTO680 at 3 different concentrations (10, 
1, and 0.1 µM). A known CTB irreversible inhibitor (F-F-FMK) was used as control at a fixed 
concentration of 10 µM. All assays were conducted in duplicate and repeated once. All the samples 
were blank (100 µl of the acetate buffer) discounted. The slope of the linear portion of the 
progression curve was used to calculate initial velocity (µM/min) with and without 
CID8795ATTO680, as well as the average of the last seven minutes of the progression curve for 
evaluating inhibition activity of the non-reactive probe on the total amount of pNA formation. The 
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statistical difference between samples (CTB, Z-Arg-Arg-pNA, and different concentrations of 
non-reactive probes or inhibitor) and baseline (CTB and Z-Arg-Arg-pNA) were measured by 
ANOVA post-hoc Dunnett’s multiple comparison test, using Prism 5 software (Prism 2018, 
November 16). A p < 0.05 was considered significant. 
 
6.2.3. Fluorescence Polarization 
In this study, anisotropy was used to verify the binding of the ATTO 680 conjugates to CTB. 
The objective of this experiment was to investigate the difference of the polarized light between 
ATTO 680 conjugates and when it is bound to CTB (Appendix section 2). The Gen5 program is 
as follows: the temperature at 37°C, filter sets as excitation at 620/40 nm, emission at 680/30 nm, 
and sensitivity was selected at 80. In all cases, black 96 well microplates were used (Costar catalog 
number 3915). Overall, anisotropy was measured at 0 and 60 minutes. After several preliminarily 
assays (mostly used CTB human (catalog number: MAK200C) with the CTB reaction buffer 
(catalog number: MAK200A) pH 7.2 at 37°C)) for both NIR probes and considering the effect of 
all the reagents which have been used in these assays, the following experiments have been 
performed for both probes. 
Subsequence to optimization results for anisotropy assays that have been done at pH 7.2, the 
binding confirmation assay for CID8795ATTO680, and CID535684ATTO680 was done with 
cathepsin B (Novoprotein, C398) in acetate at pH 5.5, corresponding to the pH of the biological 
system. Here, three CTB concentrations 100, 10, and 1 nM were used versus CID8795ATTO680 
and CID535684ATTO680 at 1, 0.1 and, 0.01 µM and anisotropy were read at zero and 60 minutes. 
The anisotropy calculated in Gen5 using Equation 5 (Appendix section 2), where the G factor 
was set as 0.87 – according to Gen5 manufacture. The parallel and perpendicular intensity readings 
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have been corrected by blank subtraction (100 µL acetate buffer at pH 5.5) to minimize the 
background contributions. These assays were performed in duplicate.  
From the results of this section, we plotted the bar graphs to compare samples (probe/CTB) 
to the background (probe no protein) by using Prism 5 software (Prism 2018, November 16). To 
show preliminary data that suggest binding, bar graphs were utilized. If the preliminary results 
confirm binding, the next step is to build a protein concentration curve. The statistical difference 
between samples (CTB and non-reactive probes) and background (non-reactive probes no protein) 
was measured by ANOVA post-hoc Dunnett’s multiple comparison test, using Prism 5 software 
(Prism 2018, November 16). A p < 0.05 was considered significant. 
6.2.4. Fluorescence Polarization Protein Concentrations Curve 
A three-fold serial dilution with a starting CTB concentration at 0.25 to 180.68 nM was 
tested against 0.02 µM and 0.05 µM concentrations of CID8795ATTO680 in a fluorescence 
polarization assay. Assays were performed in triplicate at pH 5.5 and read at zero and 60 minutes. 
All the procedures are the same as mentioned in section 6.2.3. In the following fluorescence 
polarization experiments, we used higher concentrations of the protein (0.42, 1.26, 3.79, 11.38, 
34.13, 102.39, and 307.16 nM) versus a higher concentration of CID8795ATTO680 at 0.1 µM. 
The reason for increasing the CTB concentrations is having more probe-protein complex in the 
solution; therefore, enhancing polarization. For all assays, the coefficient of variation (CV) 
(equation 1) was used to check the quality of replicates and eliminate replicates as needed to keep 
CV lower than 10%. Generally, %CV below 5 is recommended in medicine and pharmaceutical 
research. However in life sciences, such as biology, biochemistry, and biotechnology, up to 20% 




𝐶𝑉 = 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑀𝑒𝑎𝑛⁄ ∗ 100   Equation 1 
From these results, we would plot FP as a function of the protein concentrations at each fixed 
probe concentration. Generally, this plot has a sigmoidal shape where it begins at the polarized 
signal from the free ligand then reaches the plateau which is responsible for the maximum 
polarization corresponds to the complete binding of all fluorescent probes (Moerke 2009). In 
general, for building FP protein concentrations curves, the concentration of probe preferably 
should be low, as long as it reaches the detection limit of the instrument. In contrast, the protein 
concentration should be high enough to rise to the plateau of the curve while considering protein 
solubility limitation (Moerke 2009). The log CTB concentration versus fixed probe concentration 
was used for calculating EC50 by using a non-linear approximation to fit the curve. An R-squared 
value above 0.99 considers a good fitting model. (Hamilton, Ghert et al. 2015).  
6.2.5. Probe Aggregation 
Generally, aggregation-induced blue shift (AIBS) and aggregation-induced emission (AIE) 
are two common phenomena to prove of fluorescent probe aggregation. AIBS and AIE will occur 
when the rotation ability of the fluorescent probe restrains by a variety of factors such as; high 
viscosity of the buffer, different polarity preference of the fluorophore, temperature, and more. In 
general, fluorescence emission increase when intramolecular mobility restricted while shifting of 
spectra induced by changing in fluorescent probe environment or restriction of the twisted 
intermolecular charge transfer (TICT). Soon after the formation of aggregates, the solvent moves 
out of the aggregates; therefore, the fluorescent probe is facing different environments. 
Suppression of TICT state induced by aggregation leads to enhanced fluorescence and blue shift 
(Zhu, Yang et al. 2008). In this study, in the same fluorescence polarization experiments, change 
or shift in maximum fluorescence emission was evaluated. 
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Besides, aggregates of the conjugated fluorescent substance divided to two categories of 
electronic interactions: 1) H-aggregates or H-bond refers to side-by-side interaction manner of the 
chromophores with its closest-neighbor which cause displacement of the spectrum at higher energy 
and lower wavelength, 2) J-aggregates or J-bond occurs by head-to-tail interaction of the 
chromophores with its nearest-neighbor which cause displacement of the spectrum at lower energy 
and higher wavelength (Spano and Silva 2014). In this study, the absorbance of the 
CID8795ATTO680 at 40 µM with the CTB reaction buffer (catalog number: MAK200A) at pH 
7.2 and 37°C was measured. The Gen5 program is as follows: the temperature at 37°C, the 
wavelengths set at 300 to 700 nm. Clear 96-well microplates were used (Costar catalog number 
3370).  
6.2.6. Selectivity Assay for ATTO 680 Conjugates 
To confirm the selective binding of the CID8795ATTO680 toward cathepsin B against other 
proteins, an FP assay was performed. Bovine Serum Albumin (BSA) was subjected to FP assay 
using the NIR probe CID8795ATTO680 at 0.02 µM. BSA was chosen since it is pure, inexpensive, 
colorless, stable, and can interact with various small molecules easily (Phan, Bartelt-Hunt et al. 
2015). All assays were performed in triplicate, in acetate buffer (pH 5.5) for CTB and phosphate-
buffered saline (PBS) (pH 7.4) for BSA. Anisotropy was measured at 37ºC after 60 minutes based 
on the results of assays optimization. A two-fold serial dilution of BSA with a starting 
concentration at 0.25 nM to 180.45 nM and a two-fold serial dilution with a starting concentration 
at 0.25 nM to 180.68 nM for the CTB was used against a fixed concentration of 
CID8795ATTO680 at 0.02 µM.  
From the result of this section, we plotted bar graphs to compare the difference in anisotropy 
of the probe in the presence of CTB and BSA by using Prism 5 software (Prism 2018, November 
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16). The statistical difference between samples (CTB and non-reactive probes or BSA and non-
reactive probes) and background (non-reactive probes no protein) was measured by ANOVA post-
hoc Dunnett’s multiple comparison test using Prism 5 software (Prism 2018, November 16). A p 
< 0.05 was considered significant. All the data in this section was normalized by dividing the 
anisotropy value of the samples by the background and expressed as a percentage to have an equal 
baseline for comparison. 
 
6.2.7. Cell Lysate Assay 
The cell cultures were prepared by Sarah Niccoli, a member of Dr. Simon Lees’ team. MDA-
MB-231 (breast cancer cells) and H9C2 rat Cardio-myocytes (normal tissue cells) were cultured 
in Hyclone Dulbecco’s Modified Eagle Medium DMEM/high-glucose media containing either 
10% fetal clone III, 1% penicillin/streptomycin, 0.1% gentamicin and 1% sodium pyruvate, or 
10% fetal bovine serum and 5% antibiotics-antimycotics. Cells were grown in T75 flasks at 37°C, 
5% CO2. 
Adhered cells were washed once with PBS, trypsinized, then centrifuged to obtain a cell 
pellet. The pellet was then washed twice with PBS and re-suspended in 1 ml acetate buffer (with 
or without triton 1%). The solution was lysed using tissuelyser beads at 20 Hz for 2 sets of two 
minutes. The resulting solution was centrifuged (4oC, 10 min, 16000*g), and the supernatant 
moved to new tubes. Fifty µl was set aside for the protein concentration assay while the remaining 
lysate was used for the activity assay. A Pierce BCA protein assay (cat. # 23227) was performed 
as per manufacturer’s instructions to measure total protein concentration.  
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In the case of probe CID8795ATTO680, we wanted to compare the difference between 
anisotropy of the normal and cancer cells. We expected to see increased anisotropy in cancer cells 
due to the overexpression of CTB compared to a normal cell line (Bian, Mongrain et al. 2016). 
The assays were performed in triplicate with 1:2 serial dilutions of both cancer and normal lysate 
versus fixed concentration of the CID8795ATTO680 at 5 µM, 37ºC, pH 5.5 (acetate buffer). The 
baseline for the assay, which contained the probe and lysate buffer, was performed in duplicate. 
Fluorescence polarization was read on a Synergy 4™ plate reader (Biotek Inc) with settings as 
follows: delay of 15 minutes, followed by the addition of probe, and read for five hours with 30 
minutes’ interval. The filter sets as excitation at 620/40 nm, emission at 680/30 nm and, sensitivity 
was selected at 80. The statistical difference between samples (lysate and non-reactive probes) and 
background (non-reactive probes no lysate) was measure by ANOVA post-hoc Dunnett’s multiple 
comparison test using Prism 5 software (Prism 2018, November 16). A p < 0.05 was considered 
significant. Here we required higher probe concentration to observe changing in anisotropy due to 
having a complex nature of the cell environment. Therefore, to overcome the probe aggregation 
limitation, the probe was added within the last minute of running the experiment. 
To quantify the protein concentration of the lysate, the bicinchoninic acid (BCA) protein 
assay kit was used and BSA with serial dilution (2, 1, 0.5, 0.25, and 0.125 mg/ml) was used as a 
standard curve. The BCA assay is based on colorimetric detection – depending on the conversion 
of Cu2+ to Cu+ under alkaline conditions. 
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6.3. Result for Two Novels NIR Non-Reactive Probes 
6.3.1. Inhibition Assay for Seven Ligands  
To determine if the computationally discovered ligands have any inhibitory activity towards 
CTB, an assay was designed where all the compounds where incubated with recombinant CTB in 
the presence of the ligands. The effect of all seven ligands on AC-R-R-AFC activity was calculated 
in two ways – based on the average of the fluorescent reading of the last seven minutes which 
illustrates the highest signal from releasing AFC (Figure 35) and calculation of a slope (first few 
minutes of the linear portion of AFC formation with R2 value above 0.9) that represented the 




























































Figure 35. Inhibitor screening results in the presence of ligands in three concentrations according to the 
average of the last seven minutes of the progression curve for the AC-R-R-AFC substrate. F-F-FMK is a 
known CTB inhibitor and was used as the control. The dotted line marks the 70% activity threshold and 
maximum activity marked as 100%. Ligands were tested at 100 μM (black), 10 μM (gray), and 1 μM 
(light gray) in duplicates. The experiment was performed at pH 7, and a temperature of 37°C. The 
concentration of the substrate, F-F-FMK, and CTB was fixed at 200 µM, 10 µM, and 0.5 µM, 
respectively. Statistical differences in inhibition activity were determined by ANOVA with post-hoc 
Dunnett’s multiple comparison test using Prism 5 software (Prism 2018, November 16); p < 0.05 was 





















































Figure 36. Inhibitor screening results for ligands according to the initial velocity for the first few minutes 
of the progression curve for the AC-R-R-AFC substrate. F-F-FMK is a known CTB inhibitor and was 
used as a control. The dotted line marks the 70% activity threshold and maximum activity marked as 
100%. Ligands were tested at 100 μM (black), 10 μM (gray), and 1 μM (light gray) in duplicates. The 
experiment was performed at pH 7, and a temperature of 37°C. The concentration of the substrate and, F-
F-FMK, and CTB were fixed at 200 µM, 10 µM, and 0.5 µM, respectively. Statistical differences in 
inhibition activity were determined by ANOVA post-hoc Dunnett’s multiple comparison test using Prism 
5 software (Prism 2018, November 16); p < 0.05 was considered significant and presented by **. 
The aim of using these methods for activity percent calculation is as follows: the last 7 
minutes represents the total cleavage amount of 7- Amino-4-trifluoromethyl coumarin (AFC)-
based substrate to yield AFC dye, which is fluorescent. Using the initial velocity for activity 
calculation indicates how fast the substrate cleaved to produce the AFC. Based on these 
experiments, CTB activity was not strongly inhibited by any of the parent ligands screened in the 
assay at 1, 10, and 100 M. All replicates maintained CTB activity higher than 70%. However, 
for some graphical signals, some experimental errors resulted in wide inferential bars such as 
CID8795 and CID1256741. Free CTB and F-F-FMK (known CTB inhibitor) were used as 
controls, and as expected, F-F-FMK inhibits the enzyme over 70% according to both of two 
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analyses. Based on this result, there was no inhibition activity of the free ligands against CTB 
compared to the known inhibitor F-F-FMK. As it is evident from the result, the known inhibitor 
shows the maximum inhibition at the last few minutes of the assay compared to the beginning of 
the kinetics. 
6.3.2. Inhibition Assay for CID8795ATTO680 and CID535684ATTO680 
Two fluorescent probe candidates (CID8795ATTO680 and CID535684ATTO680) were 
subjected to the inhibition screening experiment at 25, 10, and 1 µM with Ac-RR-AFC substrate 
(Figure 37 and Figure 38). The test was performed duplicate for both fluorescent probes and the 
inhibition percentage calculated in two ways; the same techniques were used for the parent ligands 
as described in section 6.3.1. Inhibition assay for both NIR probes against CTB was performed 
under specific conditions as recommended in the manufacturer's instructions of the cathepsin B 
kit. The CID8795ATTO680 and CID535684ATTO680 designed to bind to CTB without inhibition 
effect on the enzyme. According to the results which are presented in Figure 37 a and b, both NIR 
probes did not show any inhibition activity against CTB more than 30%. This inhibition percentage 
was assessed based on the average of the last seven minutes of the total AFC formation. The result 
also was calculated according to the initial velocity for the first few minutes with the R2 value 
above 0.99 (Figure 38 a). Based on this result, the presence of the CID8795ATTO680 at 25 µM 
increased the activity of the enzyme to induce the rate of formation of AFC compared to the 
background for the first few minutes. In contrast, the presence of 10 µM of the CID8795ATTO680 
for the first few minutes shows approximately 15% inhibition and at 1 µM shows approximately 
20% inhibition, although none of these changes was statistically significant by ANOVA post-hoc 
Dunnett’s multiple comparison test. This result from the beginning of the assay could be the effect 
of changing the environment compared to the background. As it is shown in (Figure 38 b) the 
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CID535684ATTO680 does not have any effect on the initial velocity for commercial substrate 
(AC-RR-AFC); therefore, the binding affinity of this fluorescent-probe towards CTB was not 
enough to inhibit the protein activity. The effect of F-F-FMK as a positive control for inducing 








































Figure 37. Inhibitor screening results for ATTO 680 conjugates; CID8795ATTO680 (a) and 
CID535684ATTO680 (b) at 25, 10, and 1 µM according to the average of last seven minutes of the 
substrate (Ac-RR-AFC) progression curve. F-F-FMK is a known CTB inhibitor and was used as a 
control. The dotted line marks the 70% activity threshold and maximum activity marked as 100%. The 
experiment runs at 37°C and pH 7. The concentration of the substrate (Ac-RR-AFC) was 200 µM, and F-
F-FMK was 10 µM. The CTB concentration was 0.5 µM. Statistical differences in inhibition activity of 
samples (3 concentrations of NIR probe or F-F-FMK with a fixed concentration of substrate and CTB) 
compare to the maximum activity (only substrate and CTB) were determined by ANOVA post-hoc 
Dunnett’s multiple comparison test, using Prism 5 software (Prism 2018, November 16); p < 0.05 was 


































Figure 38. Inhibitor screening results for ATTO 680 conjugates; CID8795ATTO680 (a) and 
CID535684ATTO680 (b) according to the initial velocity for the first few minutes of the Ac-RR-AFC 
activity toward CTB. F-F-FMK is a known CTB inhibitor and was used as a control. The dotted line 
marks the 70% activity threshold and maximum activity marked as 100%. The experiment runs at 37°C 
and pH 7. The concentration of the substrate was 200 µM, and F-F-FMK was 10 µM. The CTB 
concentration was 0.5 µM. Statistical differences in inhibition activity of samples (3 concentrations of 
NIR probe or F-F-FMK with a fixed concentration of substrate) compare to the maximum activity (only 
substrate and CTB) were determined by ANOVA post-hoc Dunnett’s multiple comparison test, using 
Prism 5 software (Prism 2018, November 16); p < 0.05 was considered significant and presented by *. 
In inhibitor screening results Figure 37 and Figure 38, we did not control the potential 
interference of fluorescence from CID8795ATTO680 and CID535684ATTO680 to assess the 
effect of both NIR probes on AFC formation either on initial velocity or on the total formation of 
the AFC. Therefore, the colorimetric substrate has been used for having more reliable results. 
Inhibitor screening results for CID8795ATTO680 using a colorimetric substrate (Z-Arg-
Arg-pNA) are presented in Figure 39. This result shows the effect of the NIR probe on the 
formation of the product (pNA) by using the average of the last seven minutes and the initial 
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velocity of the reading. According to this result, no significant inhibition activity of any NIR probe 
concentrations observed compared to the baseline (free enzyme). This result would be more 
reliable due to minimizing the interference of any fluorescent wavelength of the commercial 
substrate on CID8795ATTO680. As expected, the presence of F-F-FMK shows the highest 

























































Figure 39. Inhibitor screening results for ATTO 680 conjugates CID8795ATTO680 at 10, 1, 
and 0.1 µM. a) Inhibitor screening results based on the initial velocity of the pNA formation at first ten 
minutes b) The average of the last seven minutes of the substrate (Z-Arg-Arg-pNA) progression curve 
(pNA formation). F-F-FMK is a known CTB inhibitor and was used as a control. The red dotted line 
marks the 70% activity threshold and maximum activity marked as 100%. The experiment runs at 37°C 
and pH 5.5. The concentration of the substrate (Z-Arg-Arg-pNA) was 200 µM, and F-F-FMK was 10 
µM. The CTB concentration was 0.01 µM. Statistical differences in inhibition activity of samples (3 
concentrations of NIR probe or F-F-FMK with a fixed concentration of substrate) compare to the 
maximum activity (only substrate and CTB) were determined by ANOVA post-hoc Dunnett’s 
multiple comparison test, using Prism 5 software (Prism 2018, November 16); p < 0.05 was 
considered significant and presented by ***. 
6.3.3. Fluorescence Polarization Results  
The result (Figure 40 A and B) shows changes in anisotropy induced by both NIR probes 
in the presence or absence of CTB at 100, 10, and 1 nM. According to Figure 40 A, the 
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CID8795ATTO680 at two lower concentrations (0.01 µM and 0.1 µM) show a statistical increase 
in anisotropy with the presence of the highest concentration of CTB (at 100 nM). The statistical 
increase in anisotropy also observed at 0.1 µM concentration of this probe against 10 nM of the 
CTB comply with the fluorescence polarization principle (Appendix, section 2). The rotational 
speed of the fluorophore molecule will affect directly the anisotropy value through 
dissociation/breakdown or association/binding process; therefore, at higher CTB concentration the 
presence of CID8795ATTO680/CTB complex induced increasing in anisotropy and this would be 
proof for binding interaction between CID8795ATTO680 and the target protein. The highest probe 
concentration at 1 µM indicates a high level of background compare to samples (probe with 
different concentrations of CTB). As shown in Figure 40 A, increasing the probe concentration 
resulted in a high background (free labeled-ligand); this may confirm that the CID8795ATTO680 
potentially prone to aggregation: first, the excessive concentration of the probe, which is more 
soluble in DMSO, leads to low solubility in acetate; second, comparing the anisotropy results of 
the free labeled-ligand at zero and 60 minutes indicates an increase in anisotropy over the time 
which is consistent with probe aggregation. For all the results, Raman scatters effect was 
considered by discounting the blank (only buffer). In all the results represented in Figure 40 A, 
the anisotropy at the same protein concentration was statistically the same for all probe 
concentrations. This observation confirmed the lower concentration of the NIR probe leads to the 
same anisotropy signal as the higher concentration. Although, at higher probe concentrations we 
observed increased in anisotropy in the background. This observation leads us to use 
CID8795ATTO680 at concentrations ranging from 0.01 to 0.1 µM to build the protein 
concentration curves for monitoring the behavior of this probe in the presence of different 
concentrations of protein.  
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Unfortunately, from the spectrophotometric characterization results (Figure 29) which we 
selected the probe concentrations for inhibition assay, we were unable to realize the probe 
aggregation because the FP was only measured at zero time. Although from the emission spectra, 
the excessive amount of CID8795ATTO680 (40 µM) caused self-quenching and resulted in low 
fluorescence intensity at 20 (a.u.) with the sensitivity of 90.  
None of the preliminary FP experiments for CID535684ATTO680 lead to any changes 
between background (probe no protein) and samples (probe with different concentrations of 
protein); although, this probe did indicate some anisotropy enhancing in CTB reaction buffer 
(MAK200A) at pH 7.2. Since the result was not consistent with another buffer at the same pH, we 
aborted a further investigation for CID535684ATTO680. According to all experiments which have 
been done for CID535684ATTO680, there was not sufficient evidence to confirm the binding 
interaction of this conjugated probe towards CTB at pH 5.5 (Figure 40 B). Since this probe should 












































Figure 40. Change in anisotropy in the presence and the absence of CTB (100, 10 and 1 nM) for 
CID8795ATTO680 (A) and CID535684ATTO680 (B) at 1, 0.1 and 0.01 µM. Assays were performed in 
duplicate at pH 5.5 and read at 60 minutes which were incubated for 5 minutes at 37ºC. Statistical 
differences in anisotropy were determined by ANOVA post-hoc Dunnett’s multiple comparison test, 
using Prism 5 software (Prism 2018, November 16); p < 0.05 was considered significant and presented by 




6.3.4. Fluorescence Polarization Protein Concentrations Curve 
Two experiments were performed to measure anisotropy as a function of the log of CTB 
concentrations (three-fold serial dilution starting CTB concentration at 0.25 to 180.68 nM against 
0.02 µM and 0.05 µM concentrations of CID8795ATTO680) (Figure 41 (a and b)). As a final 
experiment, a higher concentration of the probe at 0.1 µM and CTB (three-fold, serial dilution 
starting 0.42 nM to 307.16 nM) was used to indicates a better change in anisotropy compared to 
























































Figure 41. Anisotropy as a function of the log CTB concentrations started from 0.25 nM to 
180.68 nM against CID8795ATTO680 at 0.02 µM (a) and 0.05 µM (b), and the log CTB concentrations 
started at 0.42 nM to 307.16 nM against CID8795ATTO680 at 0.1 µM (c). The non-linear 
approximation curve fitting applied for measuring the EC50 of the CID8795ATTO680 by using Prism 5 
software (Prism 2018, November 16). Assays were performed in triplicate at pH 5.5 and read at 60 
minutes, which were incubated for 5 minutes at 37ºC. The average of all results (CV < 10%) shows as 
points. The dotted-line in each dataset corresponding to the binding fit model. 
 
The anisotropy results as a function of log concentrations of CTB for CID8795ATTO680 
at 0.02 µM indicates EC50 at 3.27 nM with an R2 at 0.91 Figure 41 (a). The EC50 value driven 
from this result is unreliable due to poor R2 value. Indeed, the increase in anisotropy in the presence 
of the NIR probe at 0.02 µM with different concentrations of CTB was only low enough to give 
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us the sigmoidal shape of the protein curve. The anisotropy difference between free probe and 
samples which contains different concentrations of the protein was statistically significant by 
ANOVA post-hoc Dunnett’s multiple comparison test (a p < 0.05 was considered significant) for 
the three highest concentrations of the CTB (180.68, 60.22, and 20.07). However, at the two lowest 
CTB concentrations, no increase in anisotropy was observed as compared to the background. This 
result was consistent with preliminary results which increasing in anisotropy was observed at 100 
nM of the CTB against 0.1 and 0.01 µM of the CID8795ATTO680.  
According to the preliminary results, the probe concentrations selected between 0.01 and 
0.1 µM to avoid probe aggregation. According to (Figure 41 (b and c)) which is indicated changing 
in anisotropy of the CID8795ATTO680 at 0.05 µM and 0.1 µM against serial dilution of the CTB, 
we were not able to report the EC50 values due to the poor R2 (lower than 0.5). The probe at its 
higher concentrations resulted in a higher background in the last two experiments. As mentioned 
in section 6.3.3, this probe susceptible to binding interaction to another probe like itself at high 
concentrations above 0.1 µM and over time (0 to 60 minutes). For experiments a, b, and c Figure 
41, the probe concentration was below the aggregation limit; however, preparing these 
experiments took at least one hour before running the assay compared to the single assay reported 
in section 6.3.3. Therefore, probe prone to aggregate over time and disrupt the interpretation of the 
anisotropy results. Indeed, the difference in anisotropy between free probe (0.01 and 0.1 µM) and 
probe with protein (100 nM) in preliminary results (Figure 40 A) was almost four times higher 
(assay preparation was less than 15 minutes), but this difference in FP protein concentrations curve 
assay (Figure 41 A) between free probe at 0.02 µM and probe with CTB at 180.68 nM was only 
two times higher (assay prepare almost in an hour before the run). This would be another 
interpretation for CID8795ATTO680 aggregation over time.  
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6.3.5. Probe Aggregation Results 
In the same preliminary FP experiment maximum fluorescence intensity of the samples 
(three concentrations of the CID8795ATTO680 or CID535684ATTO680 versus three 
concentrations of the CTB) and background (three concentrations of the CID8795ATTO680 or 











































Figure 42. Change in maximum fluorescence intensity at 665 nm in the presence and the absence of CTB 
(100, 10 and 1 nM) for CID8795ATTO680 (A) and CID535684ATTO680 (B) at 1, 0.1 and 0.01 µM. 
Assays were performed in duplicate at pH 5.5 and read at 60 minutes which were incubated for 5 minutes 




According to this result, the maximum fluorescence intensity for all samples and background 
was at 665 nm. For all three concentrations of both probes with protein, the increase in intensity 
observed compared to the background (free probes), although this was not statistically different 
from than background. However, at higher probes concentration (1 µM), there is a quenching trend 
of the maximum fluorescence intensity parallel to increasing the CTB concentrations, and this 
quenching is above the background (free probes). In other words, the higher probes concentration 
at 1 µM, increased the maximum fluorescence intensity compared to the background (free probes 
at acetate buffer), and this number reduced along with increasing CTB concentrations. Monitoring 
the fluorescence intensity response of CID8795ATTO680 and CID535684ATTO680 at 1 µM 
towards three concentrations of CTB compared to the background exhibits an increase in intensity 
at the 665 wavelengths higher than the two lower probe concentrations. This is due to the presence 
of an excessive amount of probes were aggregate due to its hydrophobic properties (having an 
aromatic chain) and result in poor solubility in acetate buffer. As a result, aggregation of the probes 
in the acetate holds back the non-radiation transition and then increases the fluorescence intensity 
(Huang, Wu et al. 2018). In this result, we also observed the fluorescence intensity quenched along 
with increasing the CTB concentrations at highest probes concentration (1 µM); this observation 
could be as a result of self-absorption by the fluorophore; first, the concentration of fluorophore is 
way too high, second increasing the protein concentration caused more congestion environment. 
The correlation between the hydrophobicity properties of CID8795ATTO680 and 
CID535684ATTO680 (having an aromatic chain in the dye structure) aligned with CTB 
concentration could be the reason for quenching. While the water molecules are absorbed by 
protein hydration at high protein concentrations, the environment may change accordingly, 
resulting in increasing the hydrophobicity of the external environment (Morikawa, Fujita et al. 
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2016). Therefore, upon increasing the concentration of the protein, solvent hydrophilicity may be 
reduced, which may lead to releasing the fluorophore from its bubble aggregates and reduced 
emissions accordingly. Therefore, we observed an increasing trend in anisotropy results (Figure 
40 A, CID8795ATTO680 at 1 µM) upon increasing the protein concentration; however, this 
increase is below the background.  
In all FP protein curve experiments, the maximum fluorescence intensity was also 
measured to monitor the effect of different concentrations of protein at fixed concentrations of 
CID8795ATTO680 (Figure 43). According to Figure 43 A, the maximum fluorescence intensity 
at 665 nm for all the samples (CID8795ATTO680 at 0.02 µM with different concentrations of 
CTB) and background (free CID8795ATTO680) were statistically similar, except two 
concentrations of CTB at 2.23 nM and 20.07 nM, which were below the background; however, 
these changes also were not statistically different. The results represented in Figure 41 A, was 
shown statistical increasing in anisotropy of the probes with higher protein concentrations 
compared to the background which is consistent with fluorescence intensity results presented in 
Figure 43 A. As we observed neither any quenching along with the increase in protein 
concentrations, nor a statistical increase in fluorescence intensity compared to the background. 
This result along with anisotropy result confirmed the presence of the CID8795ATTO680 at 0.02 
µM was low enough to give us the sigmoidal shape of the protein curve for EC50 calculation; 
however, the R2 value was poor (0.91). In contrast, the results presented in Figure 43 B and C, 
indicate the higher probe concentrations at 0.05 µM and 0.1 µM induced the probe aggregation. 
According to the result in Figure 43 B, the concentration of the probe was at 0.05 µM, which 
spouse to be low enough to avoid aggregation, but assay preparation was long enough to induce 
aggregation. This result represents the statistical changes in fluorescence intensity of the samples 
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compared to the background which was almost the same in the presence of different concentrations 
of CTB ranging from 2.23 nM to 60.22 nM. However, at the highest CTB concentration at 180.68 
nM, a decrease in intensity was observed compared to other concentrations of the protein (2.23 
nM to 60.22 nM). As mentioned in section 6.3.3, this quenching would be explained by the 
congestion environment caused by an excessive amount of the protein which leads to change the 
polarity of the solvent. The result presented in Figure 43 C, was also confirmed the probe 
aggregation hypothesis, where the fluorescence intensity of all samples (CID8795ATTO680 at 0.1 
µM with CTB at 3.79, 11.38, 34.13, 102.30 and 307.16 nM) was statistically above the background 
(free labeled-ligand). Besides, all the results of fluorescence intensity (preliminary and FP protein 
curves) confirmed the protein concentration above 100 nm reduces the intensity of fluorescence 
depending on the concentration of the probe. Comparing all the backgrounds with different probe 
concentrations in both preliminary and protein concentration curves results indicate a decrease in 












































































































Figure 43. Change in maximum fluorescence intensity at 665 nm as a function of the CTB concentrations 
started from 0.25 nM to 180.68 nM against CID8795ATTO680 at 0.02 µM (a) and 0.05 µM (b), and the 
CTB concentrations started at 0.42 nM to 307.16 nM against CID8795ATTO680 at 0.1 µM (c). Assays 
were performed in triplicate at pH 5.5 and read at 60 minutes, which were incubated for 5 minutes at 
37ºC. The average of all results with CV < 10% shows as a graph. The backgrounds correspond to free 
probes in acetate buffer which are represented as black columns. Statistical differences in anisotropy were 
determined by ANOVA post-hoc Dunnett’s multiple comparison test, using Prism 5 software (Prism 




In addition to AIE, monitoring any shift of the wavelength in emission spectra induced by 
aggregation of the fluorophore would be another strategy. As shown in Figure 44, there was a 
spectral shift towards lower wavelength (blue shift) for all three concentrations of the probe which 


























































Figure 44. Fluorescence emission spectrums with a blue shift. CTB concentrations started from 0.25 nM 
to 180.68 nM against CID8795ATTO680 at 0.02 µM (A) and 0.05 µM (B), and the CTB concentrations 
started at 0.42 nM to 307.16 nM against CID8795ATTO680 at 0.1 µM (C). Assays were performed in 
triplicate at pH 5.5 and read at 60 minutes, which were incubated for 5 minutes at 37ºC. Nonlinear 
regression curve fit (Gaussian) used for fitting by using Prism 5 software (Prism 2018, November 16). All 
the R2 values were above 0.99.  
As mentioned above time would be another factor to prove the probe aggregation  (Lindgren, 
Sorgjerd et al. 2005); therefore, the anisotropy of free probe at 0.02, 0.05, and 0.1 µM compared 



























Figure 45. Change in anisotropy of the free CID8795ATTO680 at 0.02 µM, 0.05 µM, and 0.1 µM over 
time (0 and 60 minutes). Assays were performed in triplicate at pH 5.5 and read at 0 and 60 minutes, 
which were incubated for 5 minutes at 37ºC. The average of all results with CV < 10% shows as a graph. 
Statistical differences in anisotropy at zero and 60 minutes were determined by ANOVA post-hoc 
Dunnett’s multiple comparison test, using Prism 5 software (Prism 2018, November 16); p < 0.05 was 
considered significant and presented by **. 
As shown in the time comparison graph, there is a statistical increase in anisotropy overtime 
for the free fluorophore that is consistent with the aggregation of the probe over time.  
As shown in Figure 46, there is an H-band observed from the absorbance spectrum of the 
CID8795ATTO680 at 40 µM. The H-band refers to side-by-side interaction of the fluorescent 
probe with its closest-neighbor (in our case to another probe like itself). CID8795ATTO680 has 
an aromatic chain in its dye structure which makes this probe hydrophobic; therefore, it is expected 
in the hydrophilic environment, this probe interacts with another probe like itself through side-by-
side interaction of the aromatic chain (Van der Waals interaction). This result would be another 
proof for probe aggregation.  
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Figure 46. Absorbance spectrum of the CID8795ATTO680 at 40 µM in CTB reaction buffer at pH 7.2 
and 37°C. The peak at lower wavelength represents the H-band induced by probe aggregation.  
 
6.3.6. Selectivity Confirmation of the CID8795ATTO680 towards CTB 
To confirm the selectivity of the CID8795ATTO680 toward CTB, a change in anisotropy of 
the probe at 0.02 μM was measured against the serial concentrations of BSA. According to the 
result shown in Figure 47, this probe did not show any statistically significant changes despite the 
serial concentrations of BSA, which would confirm the lack of binding interaction of 
















































Figure 47. Changing in anisotropy of CID8795ATTO680 at 0.02 µM in the presence of CTB and BSA. 
A) Anisotropy of the NIR probe in the presence of BSA with two-fold serial dilution with a starting 
concentration at 0.25 nM to 180.45 nM in PBS buffer pH 7.4. B) Anisotropy of the NIR probe in the 
presence of CTB with a two-fold serial dilution with a starting concentration at 0.25 nM to 180.68 nM in 
acetate buffer pH 5.5 and incubated for 5 minutes at 37ºC and read at 60 minutes. The result is based on 
the average of all triplicates (CV < 10%). Statistical differences in anisotropy were determined by 
ANOVA post-hoc Dunnett’s multiple comparison test, using Prism 5 software (Prism 2018, November 
16); p < 0.05 was considered significant and presented by **. 
 
6.3.7. Cell Lysate Result for CID8795ATTO680 
The total protein concentration was quantified based on colorimetric assay with the BCA 
kit. The result is shown in Figure 48. The total protein concentration was determined by applying 
the following equation:  
( 𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑚𝑔
𝑚𝑙






Figure 48. Average OD of the samples versus serial concentration of the BSA (2, 1, 0.5, 0.25, and 0.125 
mg/ml) to quantify the total protein concentration of the lysate. 
 
According to the BCA assay result, the total protein concentration in the MDA-MB-231 
cancer cells and H9C2 rat Cardio-myocytes normal tissue cells were 0.2432 and 0.061 mg/ml 
respectively. The two-fold serial dilution of the lysate which was used for anisotropy assay for 
cancer and normal cell are as follows: MDA-MB-231 lysate concentration (0.24, 0.12, 0.06, 0.03, 
0.01, 0.007, and 0.003 mg/ml). H9C2 lysate concentration (0.006, 0.003, 0.001, 0.0007, 0.0003, 
0.0001, and 0.00009 mg/ml). As it is obvious, the total protein concentration of the cancer lysate 
is 40 times higher than the total protein concentration of the normal cell. Here, anisotropy was read 
every 30 minutes for five hours. For the first 210 minutes, no changes observed in anisotropy 
between samples (cancer lysate and CID8795ATTO680 at 5 µM) and background (assay buffer 
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cells lysate is more reliable due to having more concentrated proteins; this result was compared 
over the last three times points. According to the Figure 49 result, for none of these three time 
points the increase in anisotropy was observed between sample (cancer lysate at 0.24 mg/ml and 
CID8795ATTO680 at 5 µM) and background (assay buffer and CID8795ATTO680 at 5 µM), 
except at 240 minutes  
In normal lysate (H9C2) (Figure 49), the samples (normal lysate at 0.006 mg/ml and 
CID8795ATTO680 at 5 µM ) were not showing any difference in the anisotropy compared to the 
background (assay buffer and CID8795ATTO680 at 5 µM). However, the concentration of the 
normal lysate was very low. According to all the results mentioned above (6.3.3 and 6.3.4), we 
corroborated the binding interaction of the CID8795ATTO680 toward CTB. However, here the 
increase in anisotropy in cancer cell lysate with 5 µM of this probe was only observed at 240 
minutes and it was only 1.1 times greater than the background; therefore, stating the binding 


























Figure 49. Change in anisotropy in the presence and the absence of MDA-MB-231 cancer cells lysate at 
0.24 mg/ml (blue graph) and H9C2 normal cells lysate at 0.0061 mg/ml (orange graph) for 
CID8795ATTO680 at 5 µM at 240, 270, and 300 minutes. Assays were performed in triplicate at pH 5.5 
and read for 300 minutes, which were incubated for 15 minutes before adding probe at 37ºC. The result is 
based on the average of all triplicates (CV < 6%). Statistical differences in anisotropy were determined by 
ANOVA post-hoc Dunnett’s multiple comparison test, using Prism 5 software (Prism 2018, November 
16); p < 0.05 was considered significant and presented by *. 
6.4. Summary and Conclusions 
Here, we evaluated the binding interaction of two novel NIR probes, CID8795ATTO680 
and CID535684ATTO680, with CTB.  
To evaluate the inhibitory activity of these two non-reactive probes and their parent ligands, 
activity assays with two commercially available substrates, Ac- Arg-Arg-AFC and Z-Arg-Arg-
pNA, was performed. According to these results, none of the parent ligands and 
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CID535684ATTO680 showed inhibitory activity on AFC formation, neither on the initial velocity 
of the progression curve nor on the last portion of the curve, which indicated the highest AFC 
formation. NIR CID8795ATTO680 probe also did not show inhibitory activity against CTB. No 
inhibitory effect had been observed in AFC and PNA formations, neither at the initial rate nor at 
the end of the progression curve.  
Given all the primary anisotropy results for CID535684ATTO680, no increase in anisotropy 
was observed between samples (probe and protein) compared to the background (free labeled-
ligand), hence further investigation was aborted.  
An increase in anisotropy was observed with the presence of lower concentrations of the 
CID8795ATTO680 (0.01 µM and 0.1 µM) with CTB concentrations at 10 nM and 100 nM in 
preliminary results. We experimentally proved that CID8795ATTO680 was susceptible to bind to 
another probe like itself. First, increased anisotropy in the background (free CID8795ATTO680) 
at high concentration; and second, increased anisotropy over time. Therefore, to build the 
anisotropy curve as a function of CTB concentrations, CID8795ATTO680 concentrations were 
selected ranging from 0.1 µM to 0.01 µM. Comply to anisotropy protein concentrations curve 
results at lower probe concentration 0.02 µM, the EC50 value defined at 3.27 ± 1.27 nM with R2 > 
0.91; however, we were not able to draw results from the higher probe concentration (0.05 µM 
and 0.1 µM) curves due to assays preparation time-consuming which cause probe aggregation and 
result in high background. Although for the first anisotropy curve as a function of CTB, we had 
the same constraint for assay preparation (timing), the probe concentration was low enough to give 
us the sigmoidal shape of the protein curve. The probe aggregation was also confirmed by 
fluorescence intensity results, which indicated the higher intensity of the probe in the presence of 
CTB at different concentrations compared to the free CID8795ATTO680 and finally by observing 
140 
 
the blue shift in the emission spectra. The absorbance spectra of the 40 µM concentration of free 
CID8795ATTO680, was also confirmed the probe aggregation due to the presence of the H-band 
in the spectrum. In conclusion, generally, the anisotropy value is not dependent on labeled-ligand 
concentration, since it is independent of the total intensity of the emission collected in both 
directions. In contrast, the intrinsic fluorescence intensity of a fluorescent probe may vary based 
on binding to another probe like itself through side-by-side interaction of the aromatic chain (Van 
der Waals) which induces a significant difference between the bound forms against free forms of 
the fluorescent probe to the total intensity of the sample. As a result, it affects the interpretation of 
the anisotropy measurements (Lea and Simeonov 2011). 
The selectivity assay of this novel probe toward CTB was determined using anisotropy assay 
against BSA. These results confirm the lack of binding of the NIR probe to BSA (no change in 
anisotropy between sample (probe and BSA) compare to the background (free probe)). In contrast, 
statistical increase (ANOVA post-hoc Dunnett’s multiple comparison test, using Prism 5 software) 
in anisotropy was observed with the presence of the same probe concentration with CTB compare 
to the background which corroborates binding interaction of CID8795ATTO680 to CTB. 
In cell lysate assay, an increase in anisotropy was found at 240 minutes of the assay in breast 
cancer cell line and this increase was only 1.1 times higher than the background (free probe in 
lysate buffer); therefore, it is difficult to conclude the binding interaction between 
CID8795ATTO680 and CTB. No change in anisotropy was observed in the cardio normal cell line 
with CID8795ATTO680 versus background (probe with lysate buffer); however, no conclusion 
can be drawn due to the low concentration of the normal lysate. 
From all the above, we may conclude that the CID8795ATTO680 in low concentration 
(below 0.02 µM) is likely to be an ideal probe for CTB in biochemistry assays by considering the 
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time factor, but most importantly, we need to evaluate the probe's behavior in intracellular protease 
in living cells.   
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Chapter 7: Rate of Hydrolysis of Cbz-Lys-Lys-PABA-DCMF by CTB and CTL 
7.1. Introduction  
Activity assays provide a quantitative measurement of the interactions between two 
molecules, usually a small molecule binding to a protein. For substrate-based probes, measuring 
hydrolysis by the target and off-target enzymes allows us to compare the relative rates of probe 
turnover assessing the specificity of the probe. Although, in vivo environments where the 
concentrations of the substrate-based probe are anticipated to be much lower, these experiments 
can be deceptive. As a solution, identifying the Michaelis−Menten parameters kcat and KM provide 
accurate measurement of the catalytic efficiency of the selected substrate toward the target 
enzyme. The specificity constant (kcat/KM), measuring the formation of the enzyme-substrate (E-
S) complex (KM) and catalytic turnover (kcat), reflects the enzymatic efficiency at low substrate 
concentrations (below the KM value) providing a better prediction of the substrate performance in 
vivo (Koshland 2002, Penuelas, Mazzolini et al. 2005). Here enzyme kinetic assays were applied 
to measure the specificity constant of the novel substrate toward CTB. The specificity constant 
value of this substrate toward CTB was determined using the Michaelis–Menten, and Lineweaver-
Burk equations. For evaluating the selectivity of the Cbz-Lys-Lys-PABA-DCMF toward CTB 
over other members of the cathepsin family, CTL was selected for the experiment – due to the 
high similarity of the active site with cathepsin B.  
7.2. Procedures and Materials for Cbz-Lys-Lys-PABA-DCMF 
7.2.1. Enzyme Kinetics  
A Michaelis-Menten curve (Appendix section 3) was generated by plotting the initial rate 
of hydrolysis of Z-Lys-Lys-PABA-DCMF versus the concentration of the substrate. For initial 
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velocity, the enzymatic hydrolysis of the Z-Lys-Lys-PABA-DCMF was measured from the slope 
of the linear portion of the reaction (the first ten points of the linear portion of the reaction). 
Recombinant CTB at 5 nM (Novoprotein, C398) was incubated with a two-fold serial dilution of 
Z-Lys-Lys-PABA-DCMF with a starting concentration at 0.019 mM to 5 mM. Prior to each 
enzymatic reaction, CTB was activated by incubation with 5 mM DTT at 37 ºC for 10 minutes. A 
7-point, 10-fold serial dilution of DCMF was used to generate a standard curve (1 to 1x10-6 mM) 
to quantify product formation as a function of substrate concentrations. Assays were performed in 
triplicate at 37°C in pH 5.5 acetate buffer (acetate 50 mM with 5 mM DTT, 5 mM EDTA, and 
0.05% Triton X-100). Fluorescence intensity was read on a Synergy 4™ plate reader (Biotek Inc.), 
every 1 minute for 170 minutes, at 470 ± 9 nm excitation and 540 ± 9 nm emission wavelengths. 
Controls containing the fluorescent substrate in the assay buffer without enzyme were used to 
evaluate the spontaneous hydrolysis and stability of the substrate throughout the kinetic 
experiments to correct for background fluorescence.  
7.2.2. The Selectivity of the Novel Substrate towards CTB 
To evaluate the selectivity of the new substrate towards CTB over a related cysteine 
protease, an activity assay was performed using recombinant human cathepsin L (R&D system, 
952-CY). The assay was performed as described in section 7.2.1 for CTB. 
7.3. Results for Cbz-Lys-Lys-PABA-DCMF 
7.3.1. Enzyme Kinetics Assay for Novel Substrate 
The results of the kinetic assay confirmed that Z-Lys-Lys-PABA-DCMF is a substrate for 





Figure 50. The reaction steps for hydrolysis of Cbz-Lys-Lys-PABA-DCMF, PABA immolation, 
and releasing DCMF. 
The rate of formation of the product (DCMF) was proportional to the substrate concentration 
at a fixed concentration of CTB at 5 nM (Figure 51). The slope of the first ten points of the linear 
portion of the curve (when the reverse reaction is not prominent) was used to calculate the initial 
velocity for each substrate concentration. The kinetics parameters KM, Vmax, and kcat were 
determined from the Michaelis–Menten and Lineweaver-Burk plots.  
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Figure 51. Lineweaver-Burk (A) and Michaelis-Menten (B) plots applied to determine kinetic 
parameters for Cbz-Lys-Lys-PABA-DCMF by using Prism 5 software (Prism 2018, November 16). 
Experiments were performed in duplicate at 5 nM concentration of CTB, pH 5.5, and temperature of 
37°C. The substrate concentration ranged from 0.019 mM to 5 mM. 
 
As shown in Table 9, Cbz-Lys-Lys-PABA-DCMF has a higher KM value (0.4 ± 0.03 mM) 
than probes Cbz-Phe-Lys-PABA-AMC and Cbz-Lys-Lys-PABA-AMC (Chowdhury, Moya et al. 
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2014). This means that Cbz-Lys-Lys-PABA-DCMF requires a higher concentration than the other 
two probes to reach half of Vmax (lower propensity to form the Michaelis-complex); however, the 
kcat value was 16.77 ± 0.4 (e.g. ~16 substrate molecules "turned over" by each enzyme active site 
per second) for Cbz-Lys-Lys-PABA-DCMF. This value is ~33 times higher than Cbz-Phe-Lys-
PABA-AMC but only half of Cbz-Lys-Lys-PABA-AMC. This resulted in a modest specificity 
constant (kcat/KM value of 41.9 ± 0.1) meaning that the new substrate is hydrolyzed ~5.5 times 
slower than Cbz-Lys-Lys-PABA-AMC.  The enzyme kinetics studies demonstrate that substrate 
5 is hydrolyzed efficiently enough to proceed into future biological experiments in cell lysates and 
living cells.  
Table 9. Comparison of kinetic constants between Cbz-Lys-Lys-PABA-DCMF and other substrate-based 
probes. Nine (9) concentration of the fluorescent substrate was used to determine KM, Vmax, and kcat values 
under the Michaelis-Menten model. Assays were performed at pH 5.5 and 37°C, with an enzyme 
concentration of 5 nM. 
Substrate KM (mM) kcat (s-1) kcat/KM 
(mM-1× s-1) 
Cbz-Lys-Lys-PABA-DCMF 0.4 ± 0.03 16.77 ± 0.4 41.9 ± 0.1 
Cbz-Phe-Lys-PABA-AMC (Chowdhury, Moya et al. 2014) 0.082 ± 0.003 0.50 ± 0.04 6.1 ± 7 
Cbz-Lys-Lys-PABA-AMC(Chowdhury, Moya et al. 2014) 0.16 ± 0.04 37 ± 2 231 ± 70 
 
7.3.2. The Selectivity of Cbz-Lys-Lys-PABA-DCMF Towards CTB and CTL 
An activity assay was performed for evaluating the selectivity of the substrate probe Cbz-
Lys-Lys-PABA-DCMF 5 toward CTB versus CTL. Due to the low catalytic turnover of this 
substrate by CTL, we were not able to calculate the initial velocity of the enzymatic reaction at 
high concentrations of the probe. Instead, an endpoint fluorescence assay was used, where 0.078 
mM of the substrate with 5 nM of the CTB was used to compare the hydrolysis of the probe by 
CTB and CTL under the same biologically relevant concentrations. The well containing CTB 
displayed a rapid and time-dependent increase in fluorescence intensity corresponding to the 
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release of DCMF. Despite being a more catalytically potent enzyme, CTL hydrolysis of the Cbz-
Lys-Lys-PABA-DCMF was much slower over the same time frame. This demonstrates that Cbz-
Lys-Lys-PABA-DCMF is hydrolyzed much faster by CTB versus CTL at this concentration of the 
probe. To put this into perspective, the endpoint RFU value, which was taken after 150 minutes 
for CTB, was approximately three times higher than the value for CTL (Figure 52). This 



























Cbz-Lys-Lys-PABA-DCMF at 0.078 mM
 
Figure 52. Selectivity assay of the Z-Lys-Lys-PABA-DCMF at a fixed concentration (0.078 mM) 
versus CTB or CTL at 5 nM. Fluorescence intensity at excitation and emission wavelengths 470 ± 9 nm 
and 540 ± 9 nm applied to evaluate the hydrolysis of Z-Lys-Lys-PABA-DCMF by CTB and CTL. A 
graph showing the endpoint RFU corresponding to releasing DCMF with CTL and CTB. 
7.4. Summary and Conclusions 
We reported that the synthesis and preliminary kinetic evaluation of Cbz-Lys-Lys-PABA-
DCMF and have shown that this compound is efficiently hydrolyzed by CTB but poorly 
hydrolyzed by CTL. The onset of fluorescence is consistent with the enzymatic release of DCMF. 
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Michaelis-Menten enzyme kinetic parameters were measured resulting in a KM = 0.4 ± 0.03 mM 
and kcat = 16.7 ± 0.4 s-1 for CTB. These parameters translated into a modest specificity constant of 
kcat/KM = 41.9 ± 0.07 mM-1× s-1. Together, these experiments suggest that Cbz-Lys-Lys-PABA-




Chapter 8: Cell Viability and Cell Imaging Assays for CID8795ATTO680 and 
Cbz-Lys-Lys-PABA-DCMF 
8.1. Introduction  
Cell viability and proliferation can be evaluated using the 3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide (MTT) assay. This assay is based on the principle that viable cells 
take up the MTT (yellow tetrazolium salt) and reduce it into an insoluble purple formazan dye by 
reductase enzymes. This dye is then released from the cells and viability can be calculated as a 
ratio of absorbance of the untreated and treated cells (Posimo, Unnithan et al. 2014). Therefore, 
cell death induced by the probe candidates can be quantified (Mosmann 1983).  
Fluorescent microscopy is a useful technique to study living cells and obtain a better 
understanding of the biological function of intracellular dynamics (Ettinger and Wittmann 2014). 
In this study, cell imaging was performed to monitored intracellular protease activity induced by 
two novel candidate probes, using the "Cytation 5" fluorescent microscope.  
8.2. Procedures and Materials  
8.2.1. Cell Viability 
For evaluation of any changes in cell viability of the MDA-MB-231 and H9C2 cell lines 
incubated with Cbz-Lys-Lys-PABA-DCMF and CID8795ATTO680, an MTT assay was 
performed. Cell viability was quantified through endpoint absorbance reads at 540 nm. The 
experiments were performed three times with samples run in triplicate each time for both probes. 
MDA-MB-231 (breast cancer cells) and H9C2 rat cardiomyocytes (normal tissue cells) were 
cultured in Hyclone DMEM/high-glucose media containing either 10% fetal clone III, 1% 
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penicillin/streptomycin, 0.1% gentamicin and 1% sodium pyruvate, or 10% fetal bovine serum and 
1% penicillin/streptomycin and 1% sodium pyruvate, respectively. Cells were maintained in T75 
flasks at 37°C, 5% CO2. For the MTT experiments, both cell types were seeded in a 96-well plate 
(Corning cat. #3596) at a concentration of 10,000 cells per well and incubated for 2 days. Media 
was then changed to 200 μL of media containing the probe candidates (at 1, 10, or 40 μM), 
followed by 20 μL of the MTT reagent (5 mg/mL stock in PBS buffer and passed through a 0.2 
μM syringe filter). The plate was incubated for 4 h at 37 °C in 5% CO2. After the media was 
removed, 200 μL of DMSO was added to the wells and shaken for 5 minutes. The viability 
percentage was calculated as a ratio of absorbance of the untreated and treated cells. All procedures 
were performed in the dark. 
8.2.2. Cell Imaging  
Once we determined that Cbz-Lys-Lys-PABA-DCMF and CID8795ATTO680 were 
chemically stable for enzymatic analysis, we evaluated the intracellular protease activity in living 
cells. MDA-MB-231 and H9C2 cells were cultured as previously described (section 9.2.1). For the 
experiment, cells were seeded into 24-well plates (Corning cat. #3526) at a concentration of 10,000 
cells per well and incubated overnight at 37 °C in a 5% CO2. To determine if hydrolysis activity 
was due to CTB, cells were then incubated for 12 hours with CA-074Me (CTB inhibitor at 10 µM) 
before incubation with substrate-based and non-reactive probes for 4 hours. Cbz-Lys-Lys-PABA-
DCMF and CID8795ATTO680 were added at concentrations of 40 and 10 μM, respectively, to 
each cell type. The intact and free probe was eliminated by washing the wells with PBS. 
Fluorescence images were then taken at (λex = 469 nm and λem = 525 nm) for Cbz-Lys-Lys-PABA-
DCMF and (λex = 628 nm and λem = 685 nm) for CID8795ATTO680 of each well using the 
Cytation 5 by BioTek. 
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8.3. Result for Two Novels NIR Non-Reactive Probes 
8.3.1. Cell Viability Results 
Based on the MTT results shown in Figure 53 A, treatment with Cbz-Lys-Lys-PABA-
DCMF across all concentrations did not significantly affect cell viability in either cell type 
(ANOVA Tukey’s multiple comparison test). However, an increase in cell viability was observed 
at the highest concentration of this substrate in H9C2 cells (healthy cells). This demonstrates that 
the presence of Cbz-Lys-Lys-PABA-DCMF does not decrease cell viability at any concentration, 
making this probe useful to detect CTB activity inside living systems. 
In contrast, cell viability was significantly reduced in both cell types following treatment 
with 40 μM of the CID8795ATTO680 to approximately 50% in (cancer cells) and 30% in (normal 
cells) compared to the untreated cells. This result suggested higher toxicity of CID8795ATTO680 
in cancer cell lines compared to normal cells at 40 µM; however, there was no toxicity observed 
at lower concentrations (10 µM and 1 µM) of this probe toward both cell lines.  Therefore, 10 μM 
of the probe was used for cell imaging.  
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Figure 53. Effects of Cbz-Lys-Lys-PABA-DCMF (a) and CID8795ATTO680 (b) on cell 
viability. MDA-MB-231 and H9C2 cells were treated with candidate probes at 1, 10, and 40 μM. 
The % viability of cells was quantified as a ratio of absorbance of the untreated and treated cells 
using MTT assay. Statistical differences in viability were determined by performing ANOVA 
post-hoc Dunnett’s multiple comparison test, using Prism 5 software (Prism 2018, November 
16); p < 0.05 was considered significant and marked by *. 
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8.3.2. Cell Imaging Results 
The final step was to observe the ability of the two candidate probes to detect intracellular 
CTB activity. As shown in Figure 54 A (resolution was set at zoom 200 µm in x and y ) and B 
(resolution was set at zoom 100 µm in x and y ), an increase in fluorescence intensity was visualized 
inside healthy cardio and cancer cells (left panel) compared to cells treated with CTB inhibitor 
(CA-074Me in the right panel). The increased intracellular fluorescence of the cells treated with 
Cbz-Lys-Lys-PABA-DCMF compared to the CA-074Me cells suggests a good CTB specificity of 
this probe in live cells. Evidently, this substrate enters into the cells, and clearly, the presence of 
the CTB inhibitor (CA-074Me) decreased the CTB activity in both cell types – leading to reduced 
activation of Cbz-Lys-Lys-PABA-DCMF.  
As shown in Figure 54 C and D (resolution was set at zoom 1000 µm in x and y), we were 
not able to observe fluorescence of the CID8795ATTO680 inside the cells; however, the 
concentration of this probe was not high enough to allow optimal fluorescent imaging and the 
filters (λex = 628 nm and λem = 685 nm) used for cell imaging did not cover the exact excitation 
maximum at 675 nm and an emission maximum at 705 nm wavelengths of the NIR probe (but 
high enough to cover the most spectrum part). For all the cell imaging different resolutions were 




Figure 54. Fluorescence microscopy and overlayer "Bright filed" images of MDA-MB-231 and 
H9C2 cell lines treated with Cbz-Lys-Lys-PABA-DCMF (A (zoom at 200 µm) and B (zoom at 100 µm) 
and CID8795ATTO680 (C (zoom at 1000 µm) and D (zoom at 1000 µm)). Fluorescent microscopy 
images taken of cells treated for 4 h with (A (cancer cells) and B (normal cells)) with 40 μM of Cbz-Lys-
Lys-PABA-DCMF (λex = 469 nm and λem = 525 nm) (C (cancer cells) and D (normal cells)) 10 μM of 
CID8795ATTO680 ((λex = 628 nm and λem = 685 nm). To evaluate probe specificity cells were treated 
with 10 μM CA-074Me for 12 hours before incubation with each probe for 4 h. In all images, the left side 
panel shows uninhibited cells versus inhibited in the right panel. 
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8.4. Summary and Conclusions 
In conclusion, we evaluated the effects of Cbz-Lys-Lys-PABA-DCMF and 
CID8795ATTO680 on cell viability using two cell lines: breast cancer (MDA-MB-231) and 
healthy cardio (H9C2). No statistically significant differences in cell viability were observed 
following treatment with Cbz-Lys-Lys-PABA-DCMF in either cell type. In contrast, the cells 
treated with CID8795ATTO680 at 40 μM resulted in approximately 50% and 30% cell death in 
cancer and normal cells, respectively. CID8795ATTO680 did not induce any significant cell death 
at lower concentrations (10 and 1 µM). These data confirm that both probes may be used for cell-
based assays, except CID8795ATTO680 which must be used at concentrations below 10 µM. 
Additionally, cell imaging results suggest Cbz-Lys-Lys-PABA-DCMF would be useful for 
detecting intercellular CTB activity using fluorescence microscopy. However, more detailed 
experiments are required to determine the intercellular location of probe hydrolysis (e.g. 
lysosomes, mitochondria, and other organelles). In contrast, no change was observed in 
fluorescence from uninhibited cells treated with CID8795ATTO680 compare to inhibited one, 
neither in breast cancer cells nor in the cardio normal cell. However, there were two main 
limitations for cell imaging of this probe; 1) using a lower concentration of the probe (10 µM) due 
to toxicity, 2) the emission and excitation wavelength used for cell imaging were almost cover the 
maximum emission and excitation of the probe. Therefore, these experiments suggest that the 
CID8795ATTO680 probe may not be an ideal probe for evaluating intracellular protease activity 




Chapter 9: Summary and Conclusions 
The present study aimed to synthesize and experimentally test novel, efficient, selective, and 
cell-permeable fluorescence probes for detecting human protease cathepsin B, a biomarker for 
cancer. This enzyme was studied from nucleotide sequence to three-dimensional structure using 
computational methods. We also investigated genetic variations of the CTSB gene based on the 
information stored in the 1,000 Genomes database. In this study, data from the 1,000 Genomes 
database suggests that identified genetic variations should not affect the binding of probes to the 
CTB active site (no SNPs found in these positions). The results also identified variants, Leu26Val 
and Ser53Gly located on the signal peptide part of the protein (which is removed before forming 
mature enzyme). Leu26Val, which this study found to be present in 39.5% of the 1,000 Genomes 
population, has been associated with chronic pancreatic cancer. 
Another achievement of this study was reporting the synthesis of two novel fluorescent 
probes: CID8795ATTO680 and CID535684ATTO680. Both have fluorescence emission in the 
near-infrared (705 nm and 690 nm, respectively), above the autofluorescence characteristic of live 
cells. Given that these probes are already fluorescent; they do not require CTB for activation. 
Although CID535684ATTO680 did not indicate a significant change in FP and anisotropy in the 
presence of CTB, future work may involve synthesizing other derivatives to increase the binding 
affinity toward CTB. Neither probe demonstrated inhibitory activity toward CTB as determined 
experimentally using the commercially available fluorogenic substrate (Ac-RR-AFC) and 
colorimetric substrate (Z-Arg-Arg-pNA).  
The NIR probe CID8795ATTO680 demonstrates no change in anisotropy toward BSA; in 
contrast, statistical increase (ANOVA post-hoc Dunnett’s multiple comparison test with p < 0.05 
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in anisotropy was observed with the same probe concentration against CTB. The preliminary 
fluorescence anisotropy result for CID8795ATTO680 indicated an increase in anisotropy in the 
presence of lower concentrations of the probe (0.01 µM and 0.1 µM) against CTB at 10 nM and 
100 nM. Compatible with the principle of fluorescence polarization (Appendix section 2), 
changing in anisotropy directly affected by the rotational speed of the fluorescent molecule 
through dissociation/breakdown or association/binding process; therefore, observing an increase 
in anisotropy between sample (probe with target protein) and background (free probe) confirmed 
the existence of CID8795ATTO680/CTB complex. From preliminary anisotropy and fluorescence 
intensity results, we proved that CID8795ATTO680 aggregation behavior induced high 
background in anisotropy (caused by excessive probe concentration and time), which was also 
consistent with fluorescence intensity, emission spectrum (blue shift observation), and anisotropy 
of the protein concentrations curve results (probe at 0.05 µM and 0.1 µM). From the anisotropy 
protein concentrations curve for CID8795ATTO680 at 0.02 µM, an EC50 value of 3.27 ± 1.27 nM 
was estimated with R2 > 0.91. Although this probe gave us the sigmoidal shape of the protein curve 
at 0.02 µM, the R2 was low for EC50 evaluation. Increased the anisotropy was observed in human 
invasive breast cancer cell line MDA-MB-231 treated with 5 µM of CID8795ATTO680 However, 
this was observed only at 240 minutes out of 10-time points (read every 30 minutes for 300 
minutes) and only 1.1 times higher compared to the background; therefore, no conclusion could 
be drawn from it. According to the cell viability results, the presence of CID8795ATTO680 at 40 
µM induced statistically significant cell death in normal (30%) and cancer (50%) cells but no 
toxicity was found at lower concentrations (10 and 1 µM). From the cell imaging results, we were 
not able to observe any fluorescence induced by CID8795ATTO680. Even though the 
CID8795ATTO680 probe that we reported was not as successful as we expected for the evaluation 
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of intracellular protease activity in living cells, these shortcomings will help us to create a better 
version of it in the future.  
In this study, a substrate-based probe Cbz-Lys-Lys-PABA-DCMF was successfully 
synthesized and evaluated for CTB hydrolysis. The selectivity of this substrate to CTB, over a 
related proteases CTL, was confirmed using fluorescence endpoint assay. The kcat/KM (41.9 ± 0.07 
mM-1× s-1) indicates that Cbz-Lys-Lys-PABA-DCMF is a good substrate for CTB. Although the 
specificity constant (kcat/KM) value of the substrate was lower than Cbz-Lys-Lys-PABA-AMC 
fluorogenic substrate (231 ± 70 mM-1× s-1) reported by Dr. Phenix’s group previously. Cell 
viability assays did not indicate any toxicity of this probe in both MDA-MB-231 (breast cancer 
cells) and H9C2 (healthy cardio cells). DCMF released by CTB was easily detected inside cells 
using fluorescence microscopy, suggesting that this fluorophore is a better choice for imaging 






Chapter 10: Future Work 
One of the most concerning diseases that attract so many scientists’ attention is cancer. 
Diagnosing cancer at initial steps of progression would be a promising method to control or even 
prevent this disease. Cathepsin B is a biomarker for cancer; therefore, monitoring its 
overexpression may be a promising strategy for cancer diagnosis (Gondi and Rao 2013). In this 
project, we synthesized, evaluated, and reported two fluorescent probes intended to target CTB. 
Recently, the combination of NIR optical imaging with fluorescent probes has become attractive 
for sensitive detection of cancers like colon, breast, and lung cancer and identification of tumors 
margins during surgeries (Habibollahi, Figueiredo et al. 2012). The next step of this project would 
be testing the substrate-based probe in different cell lines. It is also would be good to evaluate this 
substrate-based probe in an animal model for localization of cancer tumors. Modeling a new 
substrate-based probe based on the Cbz-Lys-Lys-PABA scaffold modified with NIR dyes would 
be another approach for future work. Regarding the CID8795ATTO680 probe, improving water 
solubility to prevent probe aggregation, perhaps adding DMSO (1% (v/v)) would be effective. 
Time as an important factor for probe aggregation was another limitation; therefore for future 
assays reduce the time of reading for anisotropy to 30 minutes may optimize the results. This probe 
show toxicity to the cells (MDA-MB-231 and H9C2) and aggregation in high concentration, due 
the presence of aromatic chain in its dye structure To assess toxicity, it is advisable to evaluate the 
effect of the lower concentrations of the probe ranging from 10 to 30 µM in MTT assay. For 





1. Reagents, Buffers, and Enzymes 
All buffers and reagents were obtained from Fisher Scientific or Sigma-Aldrich unless 
otherwise noted and used without further purification. Seven compounds selected from (Kamstra, 
Dadgar et al. 2014) for the experimental testing (Table 7) are as follows: CID2434131; 
CID5939530; CID667134; CID1256741; CID2999504; CID8795, and CID535684.  The 
commercially available dye used in this study called ATTO 680 NHS-ester (MW (g/mol): 
622.68866). A commercial kit used for the activity assay (Sigma Aldrich, Catalog number: 
MAK200) contained CTB reaction buffer (Sigma Aldrich, Catalog Number MAK200A) at pH 7.2, 
CTB Reagent (Sigma Aldrich, catalog number MAK200B), cathepsin B, human (Sigma Aldrich, 
catalog number MAK200C), CTB Substrate, Ac-RR-AFC (Sigma Aldrich, catalog number 
MAK200D) and CTB Inhibitor, F-F-FMK (Sigma Aldrich, catalog number MAK200E). 
Cathepsin B (CTB) was obtained from Novoprotein, C398 - 50μg at 1 mg/mL concentration. 
Supplied as a 0.2 μM filtered solution of 20 mM Tris-HCl, 150 mM NaCl, pH 8.0 with C-6His 
tag. Arg18-Ile339 and each vial contains 1 mg/mL= 27.1023 μM. acetate buffer at pH 5.5 (50 mM 
acetate with 5 mM DTT, 5 mM EDTA, and 0.05% Tween® 20).  Cathepsin L (CTL) Recombinant 
Human Cathepsin L/CTSL (C-6His) and Recombinant Human Cathepsin L (R&D system,4952-
CY), supplied as a 0.2 μm filtered solution of 20 mM HAc-NaAc, 150 mM NaCl, pH 4.5. Bovine 
Serum Albumin (Brudal, Lampe et al.) used as standard and control for the experiment (Sigma-
Aldrich catalog number P5619) at 2, 1.5, 1, 0.75, 0.5, 0.25 and 0.125 mg/ml. BSA working 




2', 7’-dichloro-6'-methoxy-fluorescein (DCMF) was synthesized by mixing one part of 
phthalic anhydride (CAS; 85-44-9, MW; 148.117 g/mol and MF; C8H4O3) to two parts of 4-
Chlororesorcinol (CAS; 95-88-5, MW; 144.554 g/mol and MF; C6H5ClO2) under the presence of 
4N Sulfuric acid (CAS; 7664-93-9, MW; 98.072 g/mol and MF; H2SO4) as the catalyzer. The 2', 
7’-dichloro-6'-methoxy-fluorescein with the chemical formula of C21H12Cl2O5 and molecular 
weight of 415.223 was conjugated with the Cbz-Lys-Lys-PABA under the presence of 4N H2SO4, 
2-(6-Methoxy-3-oxo-3H-xanthene-9-yl)-benzoic acid methyl ester. Cbz-Lys-Lys-PABA-DCMF 
(MW of 932.29 g/mol; maximum excitation at 470 nm, maximum emission at 565 nm). Cathepsin 
B commercial substrate, Z-Arg-Arg-pNA, as 10 mg lyophilized powder (Sigma-Aldrich SCP0108; 
MW 584.63; Abs=410 nm; KM (pH 7.7) = 0.78 mM and KM (pH 6.0) = 1.19 mM (Hasnain et al., 
1993 J Bio Chem 268:235-240). p-nitroaniline (pNA) (Aldrich-CAS; 100-01-6, MW; 138.126 
g/mol and MF; O2NC6H4NH2) for the standard curve. Protease inhibitor cocktail (Sigma-Aldrich 
catalog number P8340) containing two cysteine protease inhibitors, E-64 (MW 357.41 Da) at 1.4 
mM, and Leupeptin (hemisulfate salt, MW 475.59 Da) at 2 mM, in DMSO. Clear, flat bottom, 
non-binding, 96-well microplate (Fisher 12565501). Black, flat bottom, non-binding 96-well 
microplate (Costar catalog number 3915).  
2. Fluorescence Polarization and Anisotropy 
Fluorescence polarization is based on the differential rotational speed between the free small 
molecules fluorescent ligand in solution versus ligand bound to the protein of interest (Moerke 
2009). A larger molecule, including the ligand-protein complex, leads to enhanced polarization of 
light compared to the free ligand and protein.  
The equation for FP measurement is as follows: 
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𝑃 = (𝐹𝐼𝑈𝑝𝑎𝑟 − 𝐺 ∗ 𝐹𝐼𝑈𝑝𝑒𝑟)/(𝐹𝐼𝑈𝑝𝑎𝑟 + 𝐺 ∗ 𝐹𝐼𝑈𝑝𝑒𝑟)   Equation 3 
𝑚𝑃 = 𝑃/1000 
Where the FIUpar defined as fluorescent intensity is evaluated in the parallel plane, whereas 
FIUper is measured in the perpendicular plane. The G factor is the intensity ratio of the vertical to 
the horizontal component which depends on the instrument.  
Fluorescence polarization is influenced by environmental factors, such as pH-level; solution 
viscosity; absolute temperature; molecular volume, and the gas constant Equation 4 (Jameson and 
Ross 2010). Care must be taken for the recording of the experimental conditions. 
 
μ = ηV/RT   Equation 4 
where R refers to the gas constant, V is the molecular weight of the rotating molecule, T is 
the absolute temperature, and η refers to the solvent viscosity, and μ is the rotational correlation 
time of the fluorophore molecule. When all the factors remind constant, the rotational speed of the 
fluorophore will affect directly the FP value; through dissociation/breakdown or 
association/binding process.  
Anisotropy (An) is the same principle as FP; however, anisotropy is calculated using a 
different equation, and it is more accurate than FP; due to revealing the mean angular shift of the 
fluorescent molecule that induced between absorption followed by emission of the photon. This 
angular displacement influenced by the rotational diffusion rate during the lifetime of the excited 




The equation for measurement is as follows: 
𝑟 (𝐴𝑛𝑖𝑠𝑜𝑡𝑟𝑜𝑝𝑦 ) = (𝐹𝐼𝑈𝑝𝑎𝑟 − 𝐺 ∗ 𝐹𝐼𝑈𝑝𝑒𝑟)/(𝐹𝐼𝑈𝑝𝑎𝑟 + 2 ∗ 𝐺 ∗ 𝐹𝐼𝑈𝑝𝑒𝑟)  Equation 5 
𝑚𝐴 = 𝑟/1000 
Where the FIUpar and FIUper are the fluorescent intensity measured in the parallel and 
perpendicular plane respectively. The (FIUpar 2*G*FIUper) correlates to the total intensity of the 
sample. 
3. Enzyme Kinetic  
The two most common methods for determining enzyme kinetic parameters are an endpoint 
assay and continuous assay. The endpoint assay occurs when the enzymatic reaction is stopped 
after a given period and the substrate or product concentration is quantified. In contrast, a 
continuous assay refers to the quantification of substrate turnover or the formation of a product 
during the enzymatic reaction. In either case, monitoring hydrolase activity generally uses artificial 
substrates that generate a colorimetric or fluorescent signal as the reaction progresses. The kinetic 
properties of an enzymatic reaction catalyzed can be characterized by the Michaelis-Menten 
equation. The KM (mM) value refers to the substrate concentration where the reaction reaches half 
of the Vmax. The lower KM, the more propensity the enzyme must form the Michaelis complex 
reaching half Vmax at lower concentrations of substrate. The Vmax value represents the maximum 
rate of the reaction when the enzyme is saturated by the substrate at a specific enzyme 
concentration. And finally, the catalytic constant of the reaction (kcat) illustrates a number of 
substrate molecules turned over by each enzyme per unit time (Cutillas-Lozano and Gimenez 
2013). All the parameters can be defined by the following equation: 
𝑉0 =  
𝑉𝑚𝑎𝑥 [𝑆]
(𝐾𝑀+[𝑆])
   Equation 6 
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Where 𝑉0 refers to the initial velocity (concentration/time) of an enzymatic reaction, S is the 
substrate concentration in molar units, Vmax is the maximum velocity, and KM is the substrate 
concentration at half Vmax. Generally, the amount of substrate should vary at least seven points 
above and below the KM value, while the amount of enzyme is constant during the experiment. 
The initial velocity (slope of the initial curve) is calculated as the linear portion of the beginning 
of the reaction progress versus time curve at steady-state and typically has units of RFU/time or 
Abs/time (Figure 55). A standard plot of the reporter group in assay buffer is then used to convert 
units of RFU or Abs to a concentration.  Then on the XY data graph, the 𝑉0 of reaction (Y) is 
plotted against the substrate concentration (X) to generate a Michaelis-Menten plot Figure 56. 
 
 





Figure 56. Michaelis-Menten kinetics graph. The X-axis is the substrate concentration, and the 
reaction velocity is shown on the Y-axis. KM and Vmax could be defined with the following equation  
 𝑌 =  𝑉𝑚𝑎𝑥 ∗ 𝑋/(𝐾𝑚 +  𝑋)   Equation 7 
 
An alternative way to determine KM, Vmax, and kcat is the Lineweaver–Burk equation 
represented by Hans Lineweaver and Dean Burk in 1934 (Burk, Lineweaver et al. 1934). 
Historically, Lineweaver-Burk plots are the graphical representations of the Lineweaver-Burk 
equation. In Lineweaver-Burk plots (Figure 57), the slope is the ratio of KM/Vmax; X-intercept is -
1/KM and Y-intercept equal to 1/Vmax. Curve fitting programs are typically used in modern enzyme 




Figure 57. The double-reciprocal plot of Michaelis-Menten equation, Lineweaver-Burk plots (1/V versus 
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